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                                                             CHAPTER 1 
                                                General Introduction 
 
1.1 Natural products in history 
                Natural products (secondary metabolites) have been the most successful source of 
potential drug leads and impressive number of modern drugs finds their origin in natural 
products1-5. Natural products can also be prepared by chemical synthesis (including both semi 
synthetic and total synthesis) and have played a vital role in the development of the field 
organic chemistry by providing challenging synthetic targets. Natural product chemistry has 
experienced vast and diversified growth, making natural products the subject of much interest 
and promise in the present day research directed towards drug design and discovery. The 
natural products are source of new compounds with diverse structural arrangements 
possessing interesting and useful biological activities. Historically pharmaceutical companies 
have utilised plant extract to produce relatively crude therapeutic formulation, but with 
advancement of antibiotic drug formulation of fairly purified compounds have become more 
typical. 
               Natural products can come from anywhere. People most commonly think of plants 
first when talking about natural products but trees and shrubs also provide good source of 
natural compounds that can be used as basis of new therapeutic agents. Animals too, 
whether highly developed or poorly developed, whether they live on land, sea, or in 
the air can be excellent sources of natural products. Bacteria, smuts, rusts, yeasts, 
molds, fungi, and many other forms of what we consider to be primitive life can 
provide compounds or leads to compounds that can potentially be very useful 
 2 
therapeutic agents. Thus natural products have played and continue to play invaluable role in drug 
discovery. 
 3 
1.2 Medicinal plants in Folklore 
                    The natural products including plants, animals and minerals have been the basis of treatment 
of human diseases and ancient wisdom has been used in modern medicinal chemistry and will remain an 
important source in future medicine. The use of natural products has been described throughout history in 
the form of traditional medicines, remedies, potions and oils with many of these bioactive natural 
products still being unidentified. Healing with medicinal plants is an old concept for mankind. The nexus 
between man and his search for drugs in nature dates from the far past, of which there is number of 
evidence from various sources: written documents, preserved monuments, and even original plant 
medicines. Awareness of medicinal plants usage is a result of the many years of struggles against 
illnesses due to which man learned to pursue drugs in barks, seeds, fruit bodies, and other parts of the 
plants. In ancient time people looked for drugs for rescue of their diseases. In view of the fact that at the 
time there was not sufficient information either concerning the reasons for the illnesses or concerning 
which plant and how it could be utilized as a cure, everything was based on experience. Modern science 
has acknowledged their active action, mode of action, effectiveness and it has included in modern 
pharmacotherapy a range of drugs of plant origin, known by ancient civilizations and used throughout the 
millennia. The dominant source of knowledge of natural products uses from medicinal plants is a result of 
man experiencing by trial and error for hundred of centuries6-7. One example involves the plant 
genus Salvia which grows throughout the south-western region of the United States as well as 
north-western Mexico and which was used by Indian tribes of southern California as an aid in 
childbirth. Male newborn babies were “cooked” in the hot Salvia ashes as it was believed that 
these babies consistently grew to be the strongest and healthiest members of their respective 
tribes and are claimed to have been immune from all respiratory ailments for life. The plant, 
Alhagi maurorum Medik (Camels thorn) secretes a sweet, gummy material from the stems 
and leaves during hot days. This gummy sap is called “manna” and consists mostly of 
melezitose, sucrose and invert sugar and it has been documented and claimed by the 
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Ayurvedic people that the plant aids in the treatment of anorexia, constipation, dermatosis, 
epistaxis, fever, leprosy, and obesity8. It was also used by the Israelis who boiled the roots 
and drank the extract as it stopped bloody diarrhea. The Konkani people smoked the plant for 
the treatment of asthma, whilst the Romans used the plant for nasal polyps8. The plant 
Ligusticum scoticum Linnaeus found in Northern Europe and Eastern North America was 
eaten raw first thing in the morning and was believed to protect a person from daily 
infection9; the root was a cure for flatulence10-12, an aphrodisiac and was used as a sedative in 
the Faeroe Islands10, 13. Atropa belladonna Linnaeus (deadly nightshade) is found in central 
and Southern Europe, Western Asia, North Africa, North America and New Zealand. Its 
notoriously poisonous nature (three berries are sufficient to kill a child) firmly excluded it 
from the folk medicine compilation and seemed to have been accepted as dangerous to handle 
or to experiment with14. 
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1.3 Types of Natural products 
Natural products broadly divided into four parts 
1.3.1 Natural products from microorganisms 
1.3.2Natural products from plant sources 
1.3.3 Natural products from marine sources 
1.3.4 Natural products from animal sources 
 
1.3.1 Natural products from microorganisms 
             Microorganisms are capable of producing natural products with widely divergent 
structures. Greatest attention in the past has been paid to natural products that have antibiotic 
properties. Microorganisms have wide variety of potentially active substances so a large 
number of terrestrial and marine microorganisms have been taken great tool of antibiotics. 
          One of the most famous natural product discoveries derived from a fungus 
(microorganism) is that of penicillin (1) from the fungus, Penicillium notatum discovered by 
Fleming in 192915. A countercurrent extractive separation technique which produced 1 in 
high yields was required for the in vivo experimentation that ultimately saved countless lives 
and won Chain and Florey (together  with  Fleming)  the  1945  Nobel  prize  in  Physiology  
and  Medicine16.  This discovery led to the re-isolation and clinical studies by Chain, Florey 
and co-workers in the early 1940s and commercialization of synthetic penicillins, which 
ultimately  revolutionized  drug  discovery research17-20. 
              There was huge worldwide research to discover new antibiotics from 
microorganisms and bioactive natural products after preliminary research on penicillin20-21. 
Up until 1968, old methods for detecting β-lactams were still being utilized and it was 
concluded that all natural β-lactams had been discovered. Nevertheless, this was not the case 
as with the introduction, in the 1970s, of new screening methods, the production of bacterial 
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strains supersensitive to β-lactams, tests for the inhibition of β-lactamases and specificity for 
sulphur- containing metabolites resulted in the discovery of novel antibiotic structural classes 
(nocardicins, carbapenems and monobactams) including the isolation of the antibiotics, 
nocardicin (2), imipenem (3)  and  aztreonam  (4),  respectively (Figure  1)21-23.A number of 
β-lactams (cephalosporins, carbapenems and  penems) have reached the clinical practice, 
along with the novel class of broad spectrum antibiotics called the glycylcyclines23. 
 
Figure 1 
        Structure of Penicillin (1), Nocardicin (2), Imipenem (3)  and  Aztreonam  (4),   
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                 Vancomycin (5) a glycopeptide antibiotic produced in cultures of Amycolatopsis 
orientalis which is active against a wide range of gram-positive organisms such as 
Staphylococci and Streptococci and against gram-negative bacteria, mycobacteria and fungi,  
was approved by the FDA in 1958 (Figure 2). It is used for the treatment of severe infection 
and against susceptible organisms in patients hypersensitive to penicillin. The 14-membered 
macrocycle erythromycin (6) from Saccharopolyspora erythraea is an antibacterial drug, 
which contains propionate units (Figure 2). Erythromycin has broad spectrum activities 
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against gram-positive cocci and bacilli and is used for mild to moderate, upper and lower 
respiratory tract infections. Currently there are three semisynthetic ketolide derivatives of 
erythromycin, cethromycin (ABT-77γ, Restanza™), EP-420 (by Enanta Pharmaceuticals) 
and BAL-19403 (by Basilea) which are in clinical development. 
 
Figure 2  
Structure of Vancomycin (5), Erythromycin (6) 
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1.3.2 Natural products from plant 
               Plants have been part of our lives since beginning of time. We get numerous 
products from plants. The use of plants to heal or combat illness is probably as old as 
humankind. For centuries native people of various cultures have used plants as medicine for 
all sorts of healing. The ethnopharmacological properties have been used as a primary 
source of medicines for early drug discovery24-25. According to the World Health 
Organization (WHO), 80% of people still rely on plant-based traditional medicines for 
primary health care26 and 80% of 122 plant derived drugs were related to their original 
 8 
ethnopharmacological purpose27. The knowledge associated with traditional medicine 
(complementary or alternative herbal products) has promoted further investigations of 
medicinal plants as potential medicines and has led to the isolation of many natural 
products that have become well known pharmaceuticals.                       
           The most commonly used breast cancer drug is paclitaxel (Taxol®) (7), isolated 
from bark of Taxus brevifolia (Pacific Yew). In 1962 the United States Department of 
Agriculture (USDA) first collected the bark as part of their exploratory plant screening 
program at the National Cancer Institute (NCI) (Figure 3)28. The bark from about three 
mature 100 year old trees is required to provide 1 gram of 7 given that a course of 
treatment may need 2 grams of the drug. Current demand for 7 is in the region of 100–200 
kg per annum (i.e., 50,000 treatments/year) and is now produced synthetically. The first of 
several FDA approvals for various uses for Taxol® was announced in 1992 29. Taxol® (7) is 
present in limited quantities in natural sources, but its synthesis (though challenging and 
expensive) has been achieved30. Baccatin III (8) present in much higher quantities and readily 
available from the needles of T. brevifolia and associated derivatives is an example of a 
structural analogue that can be efficiently transformed into 7 (Figure 3). 
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Figure 3 
          Structure of paclitaxel (Taxol®) (7) and Baccatin III (8)    
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         Most of drugs available are not selective to cancer cells and affects normal cells as 
well, thus leading to several side effects. The aim of cancer research drug development is to 
find new drugs administrated such that they act only on target cells and not the regular 
targeting cells. One of early compounds isolated as anticancer drug was Podophyllotoxin 
(9), a compound obtained from Podophyllum peltatum in 194431.It was initially used 
therapeutically as a purgative and in the treatment of venereal warts32. Later it was found 
that it acts as an anticancer agent by binding irreversibly to tubulin33. Etoposide (10) and 
teniposide (11), two modified analogs of podophyllotoxin, however, cause cell death by 
inhibition of topoisomerase II, thus preventing the cleavage of the enzyme- DNA complex 
and arresting the cell growth34.Both these analogs are used in the treatment of various 
cancers35. 
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 Figure 4 
   Structure of Podophyllotoxin(9), Etoposide (10) and Teniposide (11). 
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          Other examples of antitumor compounds currently in clinical trials include ingenol 3-
O-angelate (12) a derivative of the polyhydroxyditerpenoid ingenol isolated from the sap of 
Euphorbia peplus (known as “petty spurge” in England or “radium weed” in Australia) 
which is a potential chemotherapeutic agent for skin cancer currently under clinical 
development by Peplin Biotech for the topical treatment of certain skin cancers36,37(Figure 5 ). 
PG490-88 (13) (14-succinyl triptolide sodium salt), a semisynthetic analogue of triptolide is 
diterpene-diepoxide isolated from Tripterygium wilfordii which is used for autoimmune and 
inflammatory diseases in the People’s Republic of China38-39. Combretastatin A-4 phosphate 
(14) a stilbene derivative from the South African Bush Willow, Combretum caffrum acts as 
an anti-angiogenic agent causing vascular shutdowns in tumors (necrosis) and is currently in 
Phase II clinical trials40- 41 
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Figure 5     
  Ingenol 3-O-angelate (12), PG490-88 (13), Combretastatin A-4 phosphate (14) 
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1.3.3 Natural products from marine sources 
            More than 70% of planet’s surface is covered by ocean and life on earth has its origin 
in the sea. In certain marine ecosystems, such as coral reefs or the deep sea floor, experts 
estimate that the biological diversity is higher than in tropical rain forests. Many marine 
organisms are soft bodied and have a sedentary life style necessitating chemical means of 
defence. Therefore, they have evolved the ability to synthesize toxic compounds or to obtain 
them from marine microorganisms. These compounds help them deter predators, keep 
competitors at bay or paralyze their prey. The overwhelming biological diversity of marine 
microbes has so far only been explored to a very limited extent. This diversity is believed to 
give rise to an equally high diversity of secondary metabolites synthesized by the marine 
microfauna and microflora42. Immense biological diversity in the sea as a whole, it is 
increasingly recognized that a huge number of natural products and novel chemical entities 
exist in the oceans, with biological activities that may be useful in the quest for finding drugs 
with greater efficacy and specificity for the treatment of many human diseases43-44.So 
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pharmaceutical companies began to realise that ocean would possess unique biodiversity and 
may be a possible source of potential drug candidates.  
            Plitidepsin (15) (also known as dehydrodidemnin B, marked by PharmaMar under the 
trade name of Aplidin) depsipeptide was isolated from the Mediterranean tunicate Aplidium 
albicans.45-46 Plitidepsin is effective in treating various cancers, including melanoma, small 
cell and non-small cell lung, bladder as well as non-Hodgkin lymphoma and acute 
lymphoblastic leukemia and is currently in Phase II clinical trials 47(Figure 6). Ecteinascidin 
74γ (ET74γ; Yondelis™) (16) was isolated in very low yields from the ascidian 
Ecteinascidia turbinate48-49. The quantities of ET743 required for advanced pre-clinical and 
clinical studies were achieved by adopting very large-scale aquaculture of E. turbinata in 
open ponds; however the semisynthesis of ET743 has been well established50-51. In October 
2007, Trabectedin also known as Ecteinascidin 743 or ET-743) (Yondelis, PharmaMar) 
became the first marine anticancer drug to be approved in the European Union. Trabectedin 
(16) has been approved by the European Agency for the Evaluation of Medicinal Products 
(EMEA) and is completing key Phase III studies in the US for approval. Spisulosine (17), 
isolated from the marine clam Spisula polynyma, exhibited substantial selective activity 
against tumor cells compared to normal cells. It advanced to Phase I clinical trials against 
solid tumors but was withdrawn in late 2006. Cryptophycin (18) was selected for clinical 
trials in the mid 1990s then advanced to phase II trials but was terminated in 2002 due to 
toxicity and lack of efficacy.52 
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Figure 6 
Structure of Plitidepsin (15), Ecteinascidin 743(16), Spisulosine (17), Cryptophycin (18) 
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1.3.4 Natural products from animals 
              The terrestrial and marine ecosystems remain nature’s most efficient synthetic 
laboratories, as they biosynthesize natural products for the survival and healing of mankind 
and generate renewable industrial and medical chemicals for the wealth of the nations. 
Animal products like their plant counterparts have been exploited throughout history to treat 
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human ailments and develop medical tools. Their usage phenomenon is marked by a broad 
geographical distribution across all continents. Animals have been source of some of 
interesting compounds that can used as drugs. Epibatidine(19) (Figure 7) a potent non-opioid 
analgesic has been isolated from skins of the Ecuadoran poison frog, Epipedobates 
tricolor53.Venom and toxins plays an important role in designing a multitude of cures for 
several diseases. Cilazapril (20) and Captopril (21), extracted from Brazilian viper are 
effective against hypertension.  
Figure 7 
Structure of Epibatidine(19) ,Cilazapril (20) and Captopril (21) 
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1.4 The Success of Natural products in drug discovery 
                An integrative approach by combining the various discovery tools and the new 
discipline of integrative biology will surely provide the key for success in natural product 
drug discovery and development. Natural products can be predicted to remain an essential 
component in the search and development for new, safe and economical medicaments. 
Pharmaceutical industry must awaken in this case to change its mindset and reorient its 
resources towards the natural product-based drug discovery programs. 
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             According to Lutz54, natural products not only complement synthetic molecules, they 
also exhibit drug- relevant features unsurpassable by any synthetic compound. One key 
feature of natural products is their enormous structural and chemical diversity. In fact, about 
40% of the chemical scaffolds found in natural products are absent in today’s medicinal 
chemistry, and therefore complementary to synthetically produced molecules. Most possibly 
this is one of the reasons for their historical success in drug discovery, with 45% of today’s 
best-selling drugs originating from natural products or their derivatives. 
          Another important advantage of natural products is that they have a biological history. 
Biosynthesis of natural products involves repeated interaction with modulating enzymes, and 
the actual biological function of many natural products comprises binding to other proteins. 
Thus, the ability of natural products to interact with other molecules, an indispensable 
prerequisite to making an effective drug, might be considered as biologically validated. It is 
an unsurprising, but often overlooked, fact that many natural products exhibit advanced 
binding characteristics compared with synthetics. Most probably, the sterically more complex 
structure of natural products contributes to this. Furthermore, natural products have higher 
molecular weights; incorporate fewer nitrogen, halogen, or sulfur atoms but more oxygen 
atoms; and are sterically more complex, with more bridgehead tetrahedral carbon atoms, 
rings, and chiral centers. 
            The success of natural products is related to the forces of natural products chemistry, 
molecular and cellular biology, synthetic and analytical chemistry, biochemistry, and 
pharmacology to exploit the vast diversity of chemical structures and biological activities of 
these products. Moreover, the exploration of structural chemical data-bases comprising a 
wide variety of chemotypes, in conjunction with databases on target genes and proteins, will 
facilitate the creation of new chemical entities through computational molecular modeling for 
pharmacological evaluation55 
 16 
          In industrialized nations at the present time, some fifty percent of all prescribed drugs 
are derived or synthesized from natural products, the only available sources for which are 
animals, marine, plants, and micro-organisms. It is considered that because of the structural 
and biological diversity of their constituents, terrestrial plants offer a unique and renewable 
resource for the discovering of potential new drugs and biological entities56. 
               There is no doubt that natural products, containing inherently large-scale structural 
diversity than synthetic compounds, have been the principal resources of biologically 
active agents and will continually act as protagonists for the discovery of new drugs. In fact, 
the value of natural products in the treatment and prevention of human diseases can be 
assessed, according to Chin et al 57. using three criteria: 1) the rate of introduction of new 
chemical entities of a wide structural diversity, including their application as templates for 
semi synthetic and total synthetic modification; 2) the number of diseases treated or 
prevented by these substances; and 3) their frequency of use in the treatment of diseases. 
Natural products are important sources for new drugs and are also good lead compounds 
suitable for further modification during drug development. The large proportion of natural 
products in drug discovery has stemmed from the diverse structures and the intricate carbon 
skeletons of natural products. Since secondary metabolites from natural sources have been 
elaborated within living systems, they are often perceived as showing more “drug-likeness 
and biological friendliness than totally synthetic molecules”, making them good candidates 
for further drug development. 
          A potential explanation beyond the success of natural products as drugs is the 
classification of natural compounds as so-called privileged structures. This concept is based 
on the fact that chemical agents produced by living organisms (particularly the secondary 
metabolites) have evolved throughout millenniums under the evolutionary pressure, and is 
therefore more likely to have a specific biological activity than “randomly” assembled, 
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manmade synthetic chemicals. Despite the enormous potential, only a minor part of globe’s 
living species has ever been tested for any bioactivity. For instance, approximately only 10% 
of all existing plant species has been assayed, and in the case of microbes the value is even 
lower. 
           In medicine, biotechnology and pharmacology, drug discovery is the process by which 
drugs are discovered and/or designed. In the past most drugs have been discovered either by 
identifying the active ingredient from traditional remedies  or  by  serendipitous  discovery.  
A new approach has been to understand how disease and infection are controlled at the 
molecular and physiological level and to target specific entities based on this knowledge. The 
process of drug discovery so long involves the identification of candidates, synthesis, 
characterization, screening, and assays for therapeutic efficacy. Once a compound has shown 
its value in these tests, it will begin the process of drug development prior to clinical trials. 
 
1.4.1 Screening and Design 
            There is vast increase in molecular targets due to increased research in molecular 
mechanism, cellular biology and genomics. So this helped to decrease drug discovery 
timeline. Major pharmaceutical industry started natural product discovery (NPD) programs 
which focused on antibacterial, antifungal as well as infectious diseases. Natural product and 
synthetic organic chemistry placed an important role and driving force for drug discovery. 
Natural product has shown potent biological activities and provided lead compound for 
treatment of cancer, microbial infection inflammation, hypercholesteremia, and tissue 
rejection in organ transplantation. 
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                However molecular target based drug discovery has replaced classical drug based 
discovery. Classical drug based discovery involves extraction, assay-based functional 
fractionation, isolation, characterization, and target validation. The advent of High 
Throughput Screening (HTS) which increased momentum in biological testing and 
combinatorial chemistry began to prompted as better approach to creating drug like 
compounds for HTS. The classical drug based discovery were not able to generate the 
numbers of target which were required to keep pace with the HTS requirements. 
           The organisation that conduct Natural product discovery (NPD) programs used 
actinomycetes, fungi, bacteria, plants and medicinal herbs as screening sources. Some apply 
invertebrates and microalgae to screening. Insects are rarely exploited. But some seek 
microbes from unusual environments. Since initial natural products are rarely launched 
unaltered as a drug, unreasonable expectations on financial investment will prevent many 
countries from being involved in the drug discovery process. The  process of finding a new 
drug against a chosen target for  a  particular  disease  usually  involves  HTS, where  large  
libraries  of  chemicals  are  tested for their ability to modify the target. One of important role 
of HTS is to show the selectivity of compounds for chosen target. The ideal condition is to 
find a molecule which should show selectivity towards only the chosen target, but not other, 
related targets. To this end, other screening runs will be made to see whether the “hits” 
against the chosen target will interfere with other related targets-this is the process of cross-
screening. Cross-screening is important, because the more unrelated targets a compound hits, 
the more likely that off-target toxicity will occur with that compound once it reaches the 
body. Though HTS is a common method used for novel drug discovery, other methods such 
as virtual high throughput screening in which screening is done using computer-generated 
models and attempting to dock virtual libraries to a target, are often used. Drug design is also 
an important method for drug discovery, where the biological and physical properties of the 
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target are studied and predication is made of the sort of chemicals that might fit into an active 
site. There is vast revolution in natural product research due to recent advancement in 
combinatorial biosynthesis, microbial genomics and screening process. Also Liquid 
Chromatography-Mass Spectrometry, Liquid Chromatography-Nuclear Magnetic Resonance 
have placed drastic role by reducing the time and cost involved in natural product research by 
using dereplication process. 
1.4.2 Dereplication 
A drug discovery program always search for novel bioactive natural products which possess 
some form of potent biological activity. Natural products (NPs) sources are well known to 
produce chemical metabolites with unique features, highly complex structures and properties 
for human health care and well-being, exhibiting a wide range of applications that have 
inspired a number of industrial arenas. There is no doubt that NPs are the most consistently 
successful source of drug leads. The dereplication is a process to indentify known compounds 
responsible for activity of extract prior to bioassay–guided isolation. At present there are 
numerous modern methods and protocols that can discriminate novel entities from natural 
compounds at early stage drug discovery programs or natural product isolation strategy. The 
isolation of novel natural products was far more frequent during 1970s and it is steadily 
declining58. Dereplication strategies generally involve combination of bioassay, separation 
science, spectroscopic methods and database searching and can be regarded as chemical or 
biological screening process. There are number of ways in which natural product program 
approach dereplication, which is based upon availability of screening 
methods/instrumentation, time and cost to identify possible biological leads or novel 
compounds from crude extract. 
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1.4.3 Chemical Diversity of Natural Products   
                Natural products remain the best sources of drugs and drug leads, and this remains 
true today despite the fact that many pharmaceutical companies have deemphasized natural 
products research in favour of HTP screening of combinatorial libraries during the past 2 
decades. Natural products possess enormous structural and chemical diversity that is 
unsurpassed by any synthetic libraries.  About 40% of the chemical scaffolds found in natural 
products are absent in today’s medicinal chemistry repertoire.  Based on various chemical 
properties, combinatorial compounds occupy a much smaller area in molecular space than 
natural products.  Although combinatorial compounds occupy a well-defined area, natural 
products and drugs occupy all of this space as well as additional volumes.  Most importantly, 
natural products are evolutionarily optimized as drug-like molecules. This is evident upon 
realization that natural products and drugs occupy approximately the same molecular space. 
Chemical diversity in nature is based on biological and geographical diversity, so researchers 
travel around the world obtaining samples to analyze and evaluate in drug discovery screens 
or bioassays. This effort to search for natural products is known as bioprospecting. On the 
other hand, some medicines are developed from a lead compound originally obtained from a 
natural source. This means that the lead compound can be produced by total synthesis, or can 
be a starting point (precursor) for a semi-synthetic compound, or can act as a template for a 
structurally different total synthetic compound. 
               This is because most biologically active natural product compounds are secondary 
metabolites with very complex structures. This has an advantage in that they are extremely 
novel compounds but this complexity also makes many lead compounds’ synthesis difficult 
and the compound usually has to be extracted from its natural source - a slow, expensive and 
inefficient process. As a result, there is usually an advantage in designing simpler analogues. 
The natural product structures have high chemical diversity, biochemical specificity and other 
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molecular properties which helped make them as lead structures for drug discovery. So it is 
helped to discriminate from libraries of synthetic and combinatorial compounds in terms of 
ratio of aromatic ring atoms to total heavy atoms, number of solvated hydrogen bond donors 
and acceptors and molecular rigidity. Natural-product libraries also have a broader 
distribution of molecular properties such as molecular mass, octanol-water partition 
coefficient and diversity of ring systems compared with synthetic and combinatorial 
counterparts. 
1.4.4 Isolation and Purification 
            Due to incomparable structural diversity and drug like properties, natural products are 
expected to play an important role as one of the major sources of new drugs so isolation of 
natural products from higher plants, marine organisms and microorganisms is therefore 
absolutely necessary, calling for state-of-the-art methodologies for separation and isolation 
procedures.The active compound has to be isolated from mixture of compounds present in 
natural sources. This isolation and purification depends on structure, stability, volatility and 
quantity of the natural compound. Often this isolation and purification is long and tedious 
which involves combination of various separation techniques. 
1.4.5 Structure-Activity Relationship (SAR) of Natural compounds 
       The analysis of SAR enables the determination of the chemical groups responsible for 
evoking a target biological effect in the organism. One of important characteristic of natural 
product is their frequent occurrence as complexes of structurally related analogues. A 
structure activity relationship relates features of a chemical structure to a property, effect, or 
biological activity associated with that chemical. In so doing there can be both qualitative and 
quantitative considerations. The fundamental premise is that the structure of a chemical 
implicitly determines its physical and chemical properties and reactivity, which, in interaction 
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with a biological system, determine its biological/toxicological properties. The process of 
developing a SAR is one of attempting to understand and reveal how properties relevant to 
activity are encoded within and determined by the chemical structure. 
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1.5 Development of New Technologies and Modern Method in Drug Discovery 
              The drug derived from natural product provided driving force for screening for 
novel, biologically active metabolite from this product. The technologies such as 
combinatorial chemistry, high-throughput screening, bioinformatics, proteomics and genomic 
play a vital role in the field of modern drug discovery. This technologies have enormous 
potential to make use of the chemical diversity of natural products. Other techniques have 
only been developed in the last years and continue to evolve rapidly. These include molecular 
diversity, compound library design, protein 3D-structures, NMR- based screening, 3D QSAR 
in modern drug design. This modern methods helped chemist to improve and accelerate the 
drug discovery research and development process. This modern method enables to screen 
100,000 test substances per week against several different targets. In keeping with these 
trends, natural products acquisition programs are now scoped to collect large numbers of 
diverse tissue samples, but only to collect small wet weights. This format allows collectors to 
provide large numbers of samples for screening, and they rely on recollection for follow-on 
studies. This means that discovery programs actively testing natural products must track a 
greater number of samples. In addition, in- formation on known natural products chemistry 
must be considered in an effort to contain the costs of follow-on studies59. 
 
1.5.1Combinatorial Chemistry 
                Combinatorial chemistry is a laboratory technique in which millions of molecular 
constructions can be synthesized and tested for biological activity.  It has generated massive 
numbers of targeted molecules for testing and the developing techniques of high throughput 
screening has automated the screening process so larger numbers of biological assays can be 
done. As compared to Natural product, libraries generated by Combinatorial chemistry are 
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relatively simple planner molecules. Combinatorial chemistry helped to reduce the time and 
the cost associated with producing effective and competitive new drugs and also can be used 
to generate new leads for a specific target as well as powerful alternative method to optimise 
the initial lead. The principle of Combinatorial chemistry depends on synthesis of directly 
large number of compounds through preparing many single compounds in parallel of many 
compound simultaneously in mixture. Increasing pressure to identify, optimize, develop, and 
commercialize novel drugs more rapidly and more cost- effectively has led to an urgent 
demand for technologies that can reduce the time to marke for new products. Molecular 
diversity, of both natural and synthetic materials, provides a valuable source of compounds 
for identifying and optimizing new drug leads. Through the rapidly evolving technology of 
combinatorial chemistry, it is now possible to produce libraries of small molecules to screen 
for novel bioactivities. This powerful new technology has begun to help pharmaceutical 
companies to find new drug candidates quickly, save significant dollars in preclinical 
development costs, and ultimately change their fundamental approach to drug discovery. 
 
1.5.2 High-Throughput-Screening 
             High-throughput screening (HTS) is the process of testing a large number of diverse 
chemical structures against disease targets to identify 'hits'. As compared to traditional 
screening methods HTS is a simple, rapid, low cost and highly efficient process. HTS 
involves an automated operation-platform, highly sensitive testing system, specific screening 
model (in vitro), an abundant components library, and a data acquisition and processing 
system. Using this  robotics researchers are able to conduct thousands of biochemical, genetic 
or pharmacological tests. Due to HTS it is easy to identify active compounds, antibodies or 
genes which modulate a particular biomolecular pathway. The results of these experiments 
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provide starting points for drug design and for understanding the interaction or role of a 
particular biochemical process in biology. Automation is an important part in HTS 
usefulness. A specialized robot is often responsible for much of the process over the lifetime 
of a single assay plate, from creation through final analysis. An HTS robot can usually 
prepare and analyze many plates simultaneously, further speeding the data-collection process. 
HTS robots currently exist which can test up to 100,000 compounds per day. HTS is 
relatively recent innovation which includes effective technologies to support the acquisition 
and inventory of the natural products sources. Information handling is key part of this 
process. Information handling requirements at every stage of this process will grow, and 
computer technology is available to meet the demand. 
 
1.5.3 Bioinformatics, Proteomics and Genomics 
              Resistance to current medical treatment plays an important role in human and animal 
health, so better resistance-breaking drugs are urgently needed. Recently, there has been a 
change in the way that medicines are being developed due to our increased understanding of 
molecular biology. In the past, new synthetic organic molecules were tested in animals or in 
whole organ preparations. This has been replaced with a molecular target approach in which 
in-vitro screening of compounds against purified, recombinant proteins or genetically 
modified cell lines is carried out with a high throughput. This change has come about as a 
consequence of better and ever improving knowledge of the molecular basis of disease. The 
major advances in genomics and sequencing means that finding an attractive target is no 
longer a problem but finding the targets that are most likely to succeed has become the 
challenge. The focus of bioinformatics in the drug discovery process has therefore shifted 
from target identification to target validation. Numerous factors must be taken into account to 
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select a candidate target from a multitude of heterogeneous resources. The types of 
information that one needs to gather about potential targets include nucleotide and protein 
sequencing information, homologues, mapping information, function prediction, pathway 
information, disease associations, variants, structural information, gene and protein 
expression data and species/taxonomic distribution among others. Different bioinformatics 
tools can be used to gather this information. The accumulation of this information into 
databases about potential targets means that the pharmaceutical companies can save 
themselves much time, effort and expense exerting bench efforts on targets that will 
ultimately fail. The information that is gathered helps to characterise the different targets into 
families and subfamilies. It also classifies the behaviour of the different molecules in a 
biochemical and cellular context. Decisions about which families provide the best potential 
targets is guided by a number of criteria. It is important that the potential target has a suitable 
structure for interacting with drug molecules. Structural genomics helps to prioritise the 
families in terms of their 3D structures. 
            The use of proteomics technology is protein mapping (separating, distinguishing, and 
quantifying the protein present in individual sample) and also involves the technique for 
indentifying specific protein and characterising their complete structure and functional role. 
The  main  protein mapping  technology  in  use  today  is  two-dimensional polyacrylamide  
gel  electrophoresis  (2D-PAGE),  which can resolve up to 2000 proteins on a single gel 
significantly better than other separation techniques. Though new technology likes HTS and 
combinatorial placed an important role, natural products still offers unprecedented structural 
diversity. The human genome has pro- vided the pharmaceutical industry with innumerable 
starting points for new drug discovery approaches. And yet, the expected flood of new 
chemical entities has failed to materialize. 
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1.6 Status of Natural products in Drug Discovery today 
                 One of most important breakthroughs in drug discovery was the use of 
mechanism-based screening for bioassay-guided fractionation and continuous improvement 
of screening formats, reagent production, robotics, and data management, mechanism-based 
screening has since become the mainstay of high-throughput screening (HTS).Though there 
is high competition from other drug discovery methods, NPs are still providing their fair 
share of new clinical candidates and drugs. This was demonstrated recently by Newman and 
Cragg who analyzed the number of NP-derived drugs present in the total drug launches from 
1981 to 201060. They concluded that NPs were still a significant source of new drugs, 
especially in the anticancer and antihypertensive therapeutic areas61. Drug discovery is a 
complex, interdisciplinary pursuit of chemistry, pharmacology, and clinical sciences, which 
has benefited humankind immensely over the last 100 years. Although drug discovery has 
been traditionally a difficult and expensive process, the amount of money currently being 
invested in R&D and clinical development has skyrocketed, while the output of newly 
launched drugs has fallen. Given that NPs have historically provided many novel drugs leads, 
one would assume that NPs would still play a pivotal role in the drug discovery strategy of 
Big Pharma. However, most Big Pharma companies have terminated or significantly scaled 
down their NP operations in the last 10 years. To a certain extent the downsizing or 
termination of these NP research programs has been offset by biotech companies offering 
NP-related services such as pure NP libraries and more traditional extract based screening 
services. To better understand why Big Pharma has scaled down its NP research programs, it 
is prudent to examine the differences between the pharmaceutical industry of today and that 
of 10-20 years ago. 
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1.7 Natural product based drugs approved during 2005-2010 
          A total of 19 NP based drugs were approved for marketing worldwide in between the 
year β005 to β010 among of which 7 are classiﬁed as NPs, 10 as semi-synthetic NPs, and 2 as 
NP derived drugs. Sativex (GW Pharmaceuticals) is the world’s ﬁrst pharmaceutical 
prescription medicine derived from the cannabis plant62. Sativex, a mixture of dronabinol and 
cannabidol , was launched in Canadian April 2005 for neuropathic pain relief in multiple 
sclerosis63 and it was also approved by Health Canada in August 2007 as an adjunctive 
analgesic for severe pain in advanced cancer patients, reducing the need for the opioid 
medications. Sativex efﬁciently reduces pain in patients with advanced cancer and has been 
recommended by the FDA for direct entry into Phase III trials. In November 2009, GW 
Pharmaceuticals disclosed that recruitment for a Phase II/III cancer pain trial of Sativex had 
been completed. In March 2010, GW Pharmaceuticals provided an update on the progress of 
regulatory submission for Sativex oromucosal spray for the treatment of the symptoms of 
spasticity due to multiple sclerosis. 
       Fumagillin (Flisint, Sanoﬁ-Aventis), an antimicrobial lead capable of inhibiting the 
proliferation of endothelial cells, was isolated from Aspergillus fumigatus64. In September 
2005, France approved Fumagillin against intestinal microsporidiosis, a disease caused by the 
sporeforming unicellular parasite Enterocytozoon bieneusi, causing chronic diarrhea in 
immunocompromised patients65. There are presently nine ȕ -lactams (two cephalosporins, six 
carbapenems and one penem) in clinical trials or undergoing drug registration. Among 
carbapenem-type ȕ -lactams, doripenem and thienamycin are the ultra-broad spectrum 
injectable antibiotics. Doripenem (Finibax, Doribax) exhibiting a broad antibacterial 
spectrum was launched in Japan by Shionogi & Co. in 2005. In October 2007, Johnson 
&Johnson (J&J) obtained formal FDA approval for use of Doripenem in intra-abdominal and 
urinary tract infections.  
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                  Tigecycline (Tygacil) is among a new generation of antibiotics called glycylcyclines, 
and is structurally similar to tetracycline. It contains a centralized four-ring carbocyclic 
skeleton substituted at the D-9 position conferring broad spectrum activity. Tigecycline 
effectively binds to the 30S subunit of bacterial ribosome and blocks the entry of amino-acyl 
tRNA molecules into the A site of the ribosome, thus inhibiting protein translation66. 
Tigecycline was developed by Wyeth and in June 2005 the FDA approved it for treatment of 
complicated skin and skin structure infections (cSSSIs) and intra-abdominal infections. 
Tigecycline was approved in Europe in May 2006, and a supplemental NDA for community 
acquired pneumonia (CAP) was submitted to the FDA in October 2007. 
             Ziconotide (Prialt) is a synthetic form of the peptide ω-conotoxin, which was isolated 
from the toxinof Conus magus, is an N-type voltage sensitive calcium channel blocker and is 
proposed to regulate neurotransmission by inhibiting pro-nociceptive neurochemical releases 
in the brain and spinal cord, thus causing pain relief67. Zotarolimus, a derivative of sirolimus, 
is the active principle of the EndeavorTM stent that inhibits cell proliferation, preventing scar 
tissue formation and minimizing restenosis in angioplasty patients68. Anidulafungin (EraxisTM 
in the US, EcaltaTM in Europe), is a semisynthetic derivative of the fungal metabolite 
echinocandin B. Anidulafungin was originally developed for use against invasive and 
oesophageal candidiasis and candidemia by Eli Lilly and was licensed to Vicuron 
Pharmaceuticals, which was purchased by Pﬁzer in June β005. Exenatide (Byetta@), is a 39 
amino acid peptide, structurally similar to glucagon-like peptide-1 (GLP-1) and was isolated 
from the oral secretions of the poisonous lizard Heloderma suspectum (Gila monster). Among 
the incretin (human hormone) mimetics, Exenatide can mimic the antidiabetic or glucose-
lower in properties of incretins. Lisdexamfetamine (VyvanseTM, NRP104) consisting of 
dextroamphetamine coupled with the essential amino acid L-lysine was designed by New 
River Pharmaceuticals to help Attention-Deﬁcit Hyperactivity Disorder (ADHD). 
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           Pleuromutilin is a metabolite of fungal origin that binds to the peptidyltransferase and 
exhibits antibacterial activity by inhibiting protein synthesis in bacteria69. Retapamulin (SB-
275833) a semi-synthetic derivative of Pleuromutilin, is the ﬁrst among pleuromutilin 
antibiotics developed by GlaxoSmithKline for topical use in impetigo caused by Gram-
positive Staphylococcus aureus or Streptococcus pyogenes. GlaxoSmithKline gained FDA 
approval for 17 in April 2007. Temsirolimus (Torisel, CCI-779) is a sirolimus derivative and 
is an intravenous drug developed by Wyeth70.It was approved by the FDA in late May 2007 
and by the EMEA in November 2007 for use against renal cell carcinoma (RCC)71. 
Temsirolimus is a semisynthetic derivative of sirolimus and is the ﬁrst mTOR inhibitor 
developed by Wyeth Pharmaceuticals. Trabectedin (Yondelis®, ecteinascidin-743, ET-743), a 
tetrahydroisoquinoline alkaloid produced by Ecteinascidia turbinate is sold by Zeltia and 
Johnson & Johnson for use in the treatment of advanced soft tissue sarcoma72. Trabectedin 
binds to the minor groove of DNA and inhibits cell proliferation by disrupting the cell cycle. 
It was approved by the EMEA in September 2007 for use against soft tissue sarcomas and 
ovarian cancer. Ixabepilone (IxempraTM, BMS-247550) is a semi-synthetic derivative of 
epothilone B produced by Sorangium cellulosum. Bristol-Myers Squibb (BMS) developed 
Ixabepilone as an anticancer drug that binds directly to ȕ-tubulin subunits on microtubules, 
leading to the suppression of microtubule dynamics, blocking of cells in the mitotic phase, 
ultimately leading to cell death.  
             Methylnaltrexone (MOA-728, Relistor® by Wyeth), an N methyl derivative of 
naltrexone, contains a charged tetravalent nitrogen atom and is unable to cross the blood-
brain barrier, and so has antagonist effects throughout the body. Methylnaltrexone blocks 
peripheral opioid receptors activated by opioids administered for pain relief and is thus useful 
in management of alcohol and opioid dependence73. Everolimus (LuveniqTM or LX211), a 
mTOR inhibiting derivative  is marketed as an immunosuppressant by Novartis under the 
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trade Aﬁnitor® for use in advanced renal carcinoma. In March 2009 the FDA has approved 
Everolimus against advanced renal cell carcinoma after failure of Sutent (sunitinib) or 
Nexavar (sorafenib)74.Telavancin (VibativTM,TD-6424), a semi-synthetic analog of 
vancomycin  inhibits bacterial growth through binding to the D-Ala-D-Ala terminus of the 
bacterial peptidoglycan precursors75. Romidepsin (depsipeptide, FK228, FR901228,Istodax®) 
a naturally occurring histone deacetylase inhibitor obtained from the bacteria 
Chromobacterium violaceum, was developed and evaluated by Gloucester Pharmaceuticals in 
various Phase I/II trials sponsored by the National Cancer Institute (NCI) for use against 
cutaneous and peripheral T-cell lymphoma (TCL)76.  
Capsaicin an active component of chili peppers belonging to the genus Capsicum, was ﬁrst 
isolated in pure and crystalline form by John Clough Thresh in 1876. Capsaicin  produces a 
burning sensation when it comes in contact with tissues though binding to the ion channel 
receptor vanilloid receptor subtype (VR 1). In November 2009, NeurogesX gained FDA 
approval for Qutenza® (a transdermal 8% patch of Capsaicin) against neuropathic pain 
combined with post-therapeutic neuralgia. In April 2010, NeurogesX launched Qutenza® in 
US and is planning to market it in Europe by Astellas Pharma Europe Ltd. 
 Aztreonam lysine (CaystonTM), an inhaled lysine salt formulation, wherein the ȕ-lactam ring 
is alone and not fused o another ring, has been evaluated by Gilead in various Phase III trials 
against cystic ﬁbrosis (CF) in patients having a pulmonary infection of the Gram-negative 
bacteria Pseudomonas aeruginosa . 
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NP-Derived drugs launched since 2005, lead compound, classification, therapeutic areas 
Year Generic name(trade 
name) 
Lead compound  classification Diseases area 
2005 Dronabinol/ /Cannabidol  Dronabinol NP Pain 
2005 Fumagillin Fumagillin NP Antiparasitic 
2005 Doripenem  Thienamycin NP-Derived Antibacterial 
2005 Tigecycline Tetracycline Semi-
synthetic NP 
Antibacterial 
2005 Ziconotide Ziconotide NP Pain 
2005 Zotarolimus Sirolimus Semi-
synthetic NP 
Cardiovascular 
surgery 
 
2006 Anidulafungin Echinocandin Semi-
synthetic NP 
Antifungal 
2006 Exenatide Exenatide-4 NP Diabetes 
2007 Lisdexamfetamine Amphetamine NP-Derived ADHD 
2007 Retapamulin Pleuromutilin Semi-
synthetic NP 
Antibacterial 
2007 Temsirolimus Sirolimus Semi-
synthetic NP 
Oncology 
2007 Trabectedin Trabectedin NP Oncology 
2007 Ixabepilone Epothilone B Semi-
synthetic NP 
Oncology 
2008 Methylnaltrexone Naltrexone Semi-
synthetic NP 
Pain 
2009 Everolimus Sirolimus Semi-
synthetic NP 
Oncology 
2009 Telavancin Vancomyci Semi-
synthetic NP 
Antibacterial 
2009 Romidepsin Romidepsin NP Oncology 
2009 Capsaicin Capsaicin NP Pain 
2010 Monobactam aztreonam Aztreonam Semi-
synthetic NP 
Antibacterial 
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Antibacterial drugs from 1981 to 2010 by generic name within source 
Generic name Trade name Year introduced Source 
Carumonam Amasulin 1988 N 
Deptomycin Cubicin 2003 N 
Insepamicin Isepacin 1988 N 
Miokamycin  Bactroban 1985 N 
Apalcillin sodium Lumota  1982 ND 
Biapenem Omegacin 2002 ND 
Cefcapene pivoxil Flomox 1997 ND 
Doripenem Finibax 2005 ND 
Fropenam Farom 1997 ND 
Tigecycline Tygacil 2005 ND 
Balafloxacin Q-Roxin 2002 S 
Besifloxacin Besivance 2009 S 
Garenoxacin Geninax 2007 S 
Grepafloxacin Vexor 1997 S 
MCV-4 Menactra 2005 V 
MenACWY-CRM Menveo 2010 V 
PsA MenAfriVac 2010 V 
N-Natural product, ND-Derived from natural product, S-Totally synthetic drug, V-Vaccine
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Antifungal drugs from 1981 to 2010 by generic name within source 
Generic name Trade name Year introduced Source 
Interferon Ȗ-n1 OGamma100 1996 B 
Anidulafungin Eraxis 2006 ND 
Caspofungin acetate Cancidas 2001 ND 
Micafungin sodium Fungard 2002 ND 
Butoconazole Femstat 1986 S 
Cloconazole HCI Pilzcin 1986 S 
Eberconazole Ebernet 2005 S 
Fluconazole Diflucan 1988 S 
Itraconazole Sporanox 1988 S 
Luliconazole Lulicon 2005 S 
Posaconazole Noxafil 2005 S 
Sertaconazole nitrate Dermofix 1992 S 
Sulconazole nitrate Exelderm 1985 S 
Soriconazole Vfend 2002 S 
Terbinafine 
hydrochloride 
Lamisil 1991 S/NM 
Liranaftate Zefnart 2000 S/NM 
                                NM-Natural product mimic, B-Biological 
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            Antiviral drugs from 1981 to 2010 by generic name within source 
Generic name Trade name Year introduced Source 
Interferon α Alfaferone 1987 B 
Interferon α -n3 Alferon N 1990 B 
Interferon ß Frone 1985 B 
Immunoglobulin 
intravenous 
Gammagard Liquid 2005 B 
Interferon alfacon-1 Infergen 1997 B 
IGIV-HB Niuliva 2009 B 
Peginterferon a-2a Pegasys 2001 B 
Peginterferon a-2b Pegintron 2000 B 
Resp syncytial virus 
IG 
RespiGam 1996 B 
Palivizumab Synagis 1998 B 
Enfuvirtide Fuzeon 2003 ND 
Maraviroc Celsentri 2007 S 
Darunavir Prezista 2006 S 
Zalcitabine Hivid 1992 S 
Amprenavir Agenerase 1999 NM 
Famciclovir Famvir 1994 S 
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        Anticancer drugs from 1981 to 2010 by generic name within source 
Generic name Trade name Year introduced Source 
Bevacizumab Avastin 2004 B 
Catumaxomab Removab 2009 B 
Celmoleukin Celeuk 1992 B 
Ibritumomab Zevalin 2002 B 
Aclarubicin Aclacin 1981 N 
Masoprocol Actinex 1992 N 
Pentostatin Nipent 1992 N 
Alitretinoin Panretin 1999 ND 
Eribulin Halaven 2010 ND 
Formestane Lentaron 1993 ND 
Mifamurtide Junovan 2010 ND 
Aminoglutethimide Cytadren 1981 S 
Fotemustine Muphoran 1989 S 
Lobaplatin Lobaplatin 1998 S 
Oxaliplatin Eloxatin 1996 S 
Ranimustine Cymerine 1987 S 
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       Antidiabetic drugs from 1981 to 2010 by generic name within source 
Generic name Trade name Year introduced Source 
Biphasic porcine 
insulin 
Pork Mixtard 30 1982 B 
Hu neutral insulin Insuman 1992 B 
Insulin aspart NovoRapid 1999 B 
Insulin glargine Lantus 2000 B 
Insulin glulisine Apidra 2005 B 
Acarbose Glucobay 1990 ND 
Extenatide Byetta 2005 ND 
Liraglutide Victoza 2009 ND 
Mitiglinide calcium 
hydrate 
Glufast 2004 S 
Repaglinide Prandin 1998 S 
Epalrestat Kinedak 1992 S 
Glimepiride Amaryl 1995 ND 
Saxagliptin Onglyza 2009 S 
Sitagliptin Januvia 2006 S 
Tolrestat Alredase 1989 S 
Nateglinide Starsis 1999 S 
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1.8 Challenges faced by Natural product synthesis 
           The natural products have made major contribution in biomedical science due to their 
broad structural diversity and interesting biological activity. So natural products have made 
major driving force for drug discovery programs in pharmaceutical industry. But major 
pharmaceutical industry have declined their focus from natural product chemistry. This 
decline has attributed to a number of factors: first, the development of combinatorial 
chemistry and introduction of high-throughput screening (HTS) against defined molecular 
targets, which prompted many companies to shift away from natural products extract 
libraries; second, the challenges associated with isolation and purification of active principles 
from complex natural product extracts; third, the lack of novel entities in natural products; 
and last, the challenges with compound supply and the lack of adequate structural 
diversification strategies for preclinical and clinical studies. However, the modest success of 
combinatorial chemistry and HTS, the considerable advances in automation of 
chromatographic and spectroscopic techniques, and the advent of genome mining, novel 
heterologous expression systems, and metabolic engineering have rekindled interest in 
natural products as valuable resources for drug discovery. At the same time, to address the 
challenges of material supply and lack of adequate structural diversification strategies, the 
organic chemistry community has been introducing new, exciting developments to natural 
product synthesis. As a consequence, natural product synthesis has become increasingly 
sophisticated. 
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1.9 Summary 
           Natural products offer a “privileged” starting point in the search for highly specific 
and potent modulators of biomolecular function. The natural product synthesis has been the 
main driving force behind the crucial contributions made by natural products to drug 
discovery and chemical biology. With the introduction of novel concepts and strategies 
inspired by the remarkable efficiency of biosynthesis, natural product synthesis in the 21st 
century is well poised to meet the challenges and complexities in natural product chemistry 
such as difficulties in material supply and lack of strategies for structural modifications. 
Therefore, by choosing the right target and using both efficient and innovative synthetic 
technology, there is no doubt that natural product synthesis will remain not only relevant, but 
also essential to progress in drug discovery and chemical biology.  
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                                                 CHAPTER 2 
 
                                           SCOPE OF THESIS 
 
             Feeding the world is an increasing challenge. On the other hand the size of arable 
land is limited and cannot be expanded without further inroads into vital natural habitats like 
the rain forests. Population growth combined with a shift to a more protein-rich diet 
containing beef and pork will increase the demand on food production in the future. As more 
people need more food per head from less land, the yields need to be increased by a 
combination of methods which is known as ‘‘Integrated Crop Management’’. This practice 
includes the selection of optimized seeds and the right locations, optimized sowing and 
harvesting techniques, crop rotation, fertilization and mechanical, biological or chemical crop 
protection. Chemical crop protection products with activity against weeds, plant diseases, 
insects and mites help the farmer to assure or increase yields. In the most drastic cases crop 
protection products can prevent the total loss of a crop. Furthermore the quality of food has 
improved and the costs of production are cheaper. Finally, the consumer can also beneﬁt from 
having access to high quality food. In modern days, we have become habitual to a wide 
variety of cheap, nutritious food which is one of the basic needs of living organisms, while 
plants are the major source of food. Rapidly growing world population put tremendous 
pressure to increase and preserve the food supply, Additionally, in recent years public 
pressure to reduce the use of synthetic pesticides in agriculture has increased. Concerns have 
been raised about both the environmental impact and the potential health risk related to the 
use of these pesticides. There are already abundant of crop protection products on the market 
and the standards of technology are high. The new agrochemicals should be target orienting 
and should have desired biological spectrum which can fulfil farmer’s needs and the 
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company’s product portfolio. Various types of pests, such as insects, fungi, weeds, bacteria, 
rodents and other biological organisms, have bothered humans or threatened human health.  
       Nature is a rich source of compounds exhibiting biological activity against weeds, plants 
diseases, insects and mites. A large number of volumes and reviews have been written about 
the use of natural products as pesticides, each having strengths and weakness when 
considering the vast array of compounds that have found use or are currently being used in 
crop protection. 
Natural products, with their tremendous structural diversity, are an important source of new 
toxophores. Many of these natural products have complex structures, insufficient biological 
activity and low persistence under field condition. Thus the share of natural products being 
used as active ingredients per se in today’s crop protection market is relatively small. In some 
cases the natural products have been further modified to provide semi-synthetic derivatives 
with improved biological properties. More importantly, natural products served as lead 
structures inspiring chemists to prepare new synthetic analogues with often improved 
biological activity, simplified structure, increased safety towards human and the environment 
an optimized persistence1.  
All the methods and technologies discussed in Chapter 1 regarding the preparation of new 
drugs can be, and are, applied for the development of new active compounds of agrochemical 
interest. 
          The need to develop new fungicides has been a major driving force for applied 
phytopathological and mycological research efforts in the past, and this is likely to remain the 
case in future as fungal plant pathogens continue to develop resistance against existing 
fungicides at great speed, and also because new disease situations continually arise. One 
increasingly stringent requirement for new fungicides is their biodegradability in natural 
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situations. This is likely to be met most readily by substances derived from natural products, 
as has already been shown for the strobilurin-derived fungicides, e.g. kresoxim-methyl. 
 A second important requirement is the selectivity of their mode of action. Ideally, a 
fungicide should prevent or cure infections by fungal plant pathogens without hitting neutral 
or benign species such as saprotrophic soil fungi or mycorrhizal associates, and of course 
without toxicity against non-fungal organisms. Non-target effects can be reduced by 
screening for fungicides which do not inhibit vegetative hyphal growth but speciﬁcally 
interfere with developmental events involved in pathogenesis, such as spore germination, 
formation of penetration structures, or sporulation. Fungi themselves are a rich source of 
secondary metabolites which can be used as ‘lead molecules’ for the development of new 
fungicides if their mode of action is sufficiently selective. 
A survey of recent literature supplies lists of novel bioactive compounds, which have been 
reported very recently and show promising biological activity. 
 Among a number of possible candidates we have selected two natural products, Leopolic 
acid A and 3-O-Methylfunicone as synthetic targets, as they have been reported to be 
endowed with fungitoxic activity.  
Thus, the aim of our thesis is to synthesize these natural products, their analogues in order to 
study the SAR and evaluation of their biological activity. 
          In chapter 3, we discuss natural compound Leopolic acid A2 with respect to isolation, 
structure elucidation, antifungal activity and study towards total synthesis of molecule. The 
unusual structure of Leopolic acid A, together with the scarcity of compounds with the 2,3-
pyrrolidinedione core in the literature, attracted our attention, so that a total synthesis of this 
compound was planned. Also we developed the idea of making analogues exploiting the 
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sequence to make SAR studies and to increase the activity.We also discuss the approach 
toward total synthesis of a positional isomer of Leopolic acid A. 
 In chapter 4 we discuss the synthesis of various compounds containing the 2,3-
pyrrolidinedione core present in Leopolic acid. 
            In chapter 5, we discuss the antifungal and antimicrobial activity of various 
intermediate containing the 2,3-pyrrolidinedione skeleton, considering a combination of 
substituents at different positions to have a large variety of structurally diverse molecules. 
The compounds were tested on S. mutans, Cladosporium cladosporioides and C. albicans 
and preliminary structure-activity relationship (SAR) have emerged. 
      In chapter 6, we discuss the efforts towards the total synthesis of 3-O-Methylfunicone. 
We also discuss the reported synthesis of 3-O-Methylfunicone based on Stille coupling 
reaction3,4. 
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                                                     CHAPTER 3 
 
                Part A: Synthetic studies towards the total Synthesis of Leopolic Acid A 
 
3.1 Introduction 
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                 Chemical analysis of a terrestrial-derived Streptomyces sp. isolated from the 
rhizosphere of the plant Juniperus excels collected from the Crimean Mountains (Ukraine) 
yielded a new acid, leopolic acid A (1)1. HRESI(+)MS analysis of 1 revealed a 
pseudomolecular ion ([M+H]+) indicative of a molecular formula (C29H43N3O6) requiring 10 
double bond equivalents. The 13C NMR (DMSO-d6) data revealed 4 ester/amide carbonyls 
(δC 157.8, 166.5, 172.5, and 174.2) and a further 8 sp2 resonances (δC 126.6 to 141.7), 
accounting for 8 DBE and requiring 2 rings. Consideration of the 1D and 2D NMR data 
revealed a mono-substituted benzene ring [COSY correlations from H-5 to H-9 extended by 
HMBC correlations to the methylene C-3 (δC 37.9) which further extended to a deshielded 
methine C-2 (δC 54.3) and the amide NH (δH 6.35). and methine H-2 (δH 4.29) to the 
ester/amide carbonyl C-1 (δC 174.2) ]. This led to the construction of the amino acid residue 
phenylalanine (C1–C10). Further examination of the 1H and COSY NMR data documented 
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an isolated spin system, indicative of two secondary methyls H3- 15 and H3-16 (δH’s 0.91 and 
0.75) extending through the deshielded methine H-13 (δH 5.36) to the amide NH (δH 6.47). 
HMBC correlations were observed from the amide NH to the ester/amide carbonyl C-17 (δC 
172.5). The generation of the fragment C-13–C-17 was reminiscent of the amino acid residue, 
valine. HMBC correlations from both the a protons H-2 (δH 4.29) and H-13 (δH 5.36) to the 
amide carbonyl C-11 (δC 157.8) linked the two amino acid residues together generating 
subunit A. The remaining structure fragment of 1, subunit B(cyclised part with long chain) 
consisted of an isolated spin system, indicative of a primary methyl H3-32 (δH 0.85) linked 
through a set of methylenes generating the aliphatic chain C-23–C-32. A deshielded 
methylene H2-22 (δH 4.00, 4.09) (δC 46.5) suggested its connectivity to a nitrogen, which in 
turn with the terminal methylene H2-23 (δH 2.30) showed HMBC correlations to one another 
and to the quaternary carbons C-20 (δC 141.7) and C-21 (δC 129.2). The downfield chemical 
of C-20 suggested its attachment to a heteroatom, in this case hydroxyl functionality (δH 
9.45). Also observed were correlations from H2-22 to an amide carbonyl C-19 (δC 166.5).  A 
large coupling (J = 18.6 Hz) for the methylene H2-22 and to accommodate for the remaining 
DBE led to the construction of the 5-dihydro-3-hydroxy-pyrrole-2-one ring (C-19–C- 22). 
Finally a HMBC correlation from the methylene H2-22 to C-17 of subunit A (Ureido moiety) 
led to the formulation of the planar structure of 1. Marfey’s analysis of 1 confirmed the 
presence of L-Phe and L-Val residues, thereby assigning a 2S, 13S configuration. 
                 Leopolic acid A (1) was identified to possess a rare ureido dipeptide, Phe-CO-
Val, attached to a 5-dihydro-3-hydroxy-pyrrole-2-one ring. Ureido-peptides with varying 
number of amino acids have been previously isolated from actinomycetes. Noteworthy 
examples of ureido peptides include the microbial alkaline protease inhibitors, (MAPI) - α 
and ȕ,2 GE20372 factor A and B, as HIV-1 protease inhibitors,3 and the pacidamycins,4 
exhibiting anti-Pseudomonas aeruginosa activity. Closest resemblance of the substituted 
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pyrrole-2- one ring is found in the tetramic acid incorporating metabolites which include the 
nocamycins, isolated from a terrestrial Nocardiopsis sp.5 Lydicamycin, isolated from 
Streptomyces showing selective Gram +ve antibacterial activity,6 and TPU-0037-B, isolated 
from the marine-derived Streptomyces sp. exhibiting antimicrobial activity against MRSA.7 
The examples were not limited to microbes but spanned to cyanobacteria, isomalyngamide A 
isolated from Lyngbya majuscule.8 
 Leopolic acid (1), has unprecedented structural features consisting of an aliphatic side chain 
attached to the novel 3-hydroxy-dihydropyrrole-2-one residue connected to the ureido 
dipeptide L-Phe-L-Val. 
3.1.1 Biological Activity 
        Leopolic acid A (1) was screened against a panel of Gram positive and negative 
bacterial strains, but it did not show significant activity. The cytotoxicity of leopolic acid A 
against HCT-116 (human colon carcinoma) cells was in the range of 20 µg/mL. However, it 
did show antifungal and antibacterial activity against Mucor hiemalis and Staphylococcus 
aureus with a MIC of 32 and 16 μg/mL, respectively. 
MIC and IC50 (µg/mL) values of leopolic acid A (1) 
Test organism MIC (µg/mL) 
Candida albicans > 64 
Pichia anomala > 64 
Mucor hiemalis    32 
Pseudomonas aeruginosa PA14 > 64 
Escherichia coli DH5a > 64 
Escherichia coli TolC > 64 
Micrococcus luteus    32 
Staphylococcus aureus Newman    16 
Bacillus subtilis     32 
Mycobacterium diernhoferi    32 
 
 IC50 (µg/mL) 
Human colon carcinoma cells HCT-116 ca. 20 
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3.2 Importance of Ureido containing compounds   
            Ureides are compounds, which essentially incorporate urea as a substructural 
component either in open or cyclic form. Ureido derivatives are one of the oldest classes of 
bioactives, widely used as antiinfective agents. Several of these compounds, including 
aminoquinuride, aminocarbalide, imidurea, cloflucarban, nitrofurazone, urosulfan, viomycin 
are used in clinical situations. The ureides are one of the most simple and commonly used 
antibacterial agents. The aryl ureas are one of the simplest of all the chemicals to be used in 
clinics. In studies reported in the middle of the last century, Beaver et al described the 
synthesis and antibacterial activity of several diarylureas9. A number of these diaryl ureas 
displayed significant antibacterial activity and triclocarban (2) was developed for the clinical 
use. In present times, triclocarban is compulsorily used in the cleansing and disinfecting 
solutions in hospitals, households, cosmetics, toys, textiles and plastics. It is active against 
gram positive bacteria and certain fungi, but less so against gram negative bacteria. It is now 
known that triclocarban disables the activity of ENR (enoyl-acyl carrier-protein reductase), 
an enzyme vital for building the cell wall of the bacteria and fungus10. Another analogous 
urea derivative the chloflucarban (3) has been reported to have similar antibacterial properties 
and commercial utility. TAN-1057A(4) isolated from Flexibacter spp. and TAN-1057A has 
been found to exhibit potent activity against several MRSA strains and was found to be very 
similar to vancomycin. An array of ureide including several peptidomimetics has been 
reported to display potent antiviral activity including anti-HIV activity. The anti-HIV agents 
comprises of the nucleosidic reverse transcriptase inhibitors, the HIV-protease inhibitors and 
the NNRTIs (non-nucleosidic reverse transcriptase inhibitors). Guieffier and coworkers 
designed the synthesis of ureidoimidazo[1,2-α]pyridine derivatives (5) for anti-HIV 
activity11. Rodgers and Cocuzza from DuPont filed a patent for 1,3-benzodiazepin-2-ones and 
1,3-benzoxazepin-2-ones (6) useful as HIV reverse transcriptase inhibitors12. They claimed 
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the treatment of HIV infection by coadministration of these compounds with at least one of 
the HIV-reverse transcriptase inhibitor and/or HIV protease inhibitor. 
Figure 1 
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3.3 Synthesis of Leopolic Acid A 
3.3.1 Retrosynthetic Approach 
Our initial retrosynthetic analysis is outlined in scheme 3.1. In the beginning we envisioned 
that Leopolic Acid A could be constructed by a convergent synthetic strategy. Our first 
strategy for the synthesis of Leopolic acid A was based on the coupling of two domains: a 
protected ureidodipeptide A and 4-decyl-3-hydroxy-1,5-dihydroxypyrrol-2-one ring B. The 
ureido dipeptide A could be constructed from commercially available L-Phenylalanine and L-
Valine and 4-decyl-3-hydroxy-1,5-dihydroxypyrrol-2-one ring B could be constructed from 
ethyl acrylate and diethyl oxalate. 
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3.3.2 Attempts towards the synthesis of subunit B 
The attempts towards the synthesis of subunit B are shown in scheme 3.2, scheme 3.3, 
scheme 3.4 and scheme 3.5. 
                 The Michael addition of p-methoxybenzylamine and benzylamine on ethyl acrylate 
7 gave respectively amine 8 and 913.The Boc and benzyl protection of the respective amines 
furnished compounds 10 and 11 with 85% and 89% yield. The LDA- and HMPA-induced α 
alkylation of these amines gave 12 and 1314.The selective deprotection of Boc and benzyl 
groups of the amines was carried out with TFA and ceric ammonium nitrate respectively. 
Several attempts for Dieckmann cyclisation of compounds 14 and 15 with diethyl oxalate and 
different bases failed. The steric hindrance of the α–decyl chain might be the reason for the 
failure of Dieckmann cyclisation. 
             Then we turned our attention to cyclise a compound before the incorporation of the 
decyl chain. Dieckmann cyclisation of Michael products 8 and 9 with diethyl oxalate, NaOEt 
furnished the 2,3-pyrrolidinones 16 and 17. As compounds with this skeleton are known to 
exist in the enolic 3-hydroxy-1,5-dihydro-pyrrol-2-one form, the enolic OH was first 
protected with a TBS group, by reacting it  with TBSCl and imidazole to give compounds  18 
and 1915. Reduction of protected enols 18 and 19 with DIBAL-H was successful and gave 
alcohol 20 and 21 in72% and 90% yield. Several oxidation conditions were carried out on the 
alcohol, but resulted into decomposition of compounds. We tried different oxidising agents 
like PCC, PDC, Swern, MnO2 and Dess-Martin. 
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Scheme 3.2 
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Reagents and Conditions: 
a) Benzylamine or p-methoxybenzylamine, EtOH, RT,12h b) BnBr, K2CO3,DMF,RT,12h and 
(Boc)2O,TEA, DCM, RT, 2h c) LDA, HMPA, Decyl iodide, THF, -78oC to RT, 12h d)TFA, 
DCM,RT, 12h and CAN, ACN:Water, RT, 4h 
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Scheme 3.3 
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Reagents and Conditions: 
a) Benzylamine or p-methoxybenzylamine, EtOH, RT,12h b) Diethyl oxalate, NaOEt, EtOH, 
Reflux, 4h c)TBSCl, Imidazole, DCM, 0o to RT, 3h d) DiBAL-H,DCM, -78oC, 2h 
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              The alcohols 20 and 21 were then converted into the corresponding bromides 22 and 
23 by Appel reaction with PPh3 and CBr416.This is shown in scheme 3.4. The bromide was 
reacted with PPh3 to give the bromonium salts 24 and 25 which were, then, subjected to 
Wittig condensation with a long chain aldehyde, nonanal, to obtain compounds 26 and 2717. 
Several attempts were carried out for deprotection of PMB protecting group but always 
resulted into decomposition of products. Deprotection was tried with the help of CAN, DDQ, 
TFA and hydrogenation. This decomposition may be attributed to the free 3-
hydroxypyrrolidinone nucleus. 
The double bond of compound 26 was, then, reduced by catalytic hydrogenation to give 
compound 28. Then we tried to remove PMB group with different reagents but resulted into 
decomposition. Also deprotection of enolic TBS group of compound 28 with TBAF resulted 
into a very unstable and temperature sensitive compound which got decomposed during water 
work up.  
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Scheme 3.4 
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Reagents and Conditions:  
a) PPh3, CBr4, DCM, 12h b) PPh3, Toluene, reflux, 5h c) n-Nonanal, LiHMDS, THF, -
78oC to RT, 5h d) H2, 10%Pd/C, RT, 1h, 89% e) TBAF, THF, OoC, 1h. 
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               In order to check the stability of compounds we changed the enolic protecting group 
and used benzyl and methyl protecting groups for enol protection. This is shown in scheme 
3.5. The enol of compound 16 was protected with benzyl and methyl by using benzyl 
bromide and methyl iodide in DMF. The DIBAL-H reduction of esters 30 and 31 furnished 
alcohols 32 and 33. The Appel reaction followed by bromination gave bromo compounds 34 
and 35.The long chain was incorporated by Wittig olefination reaction to gave 38 and 39. 
Again we carried out different attempts for removal of PMB protecting group but resulted 
into decomposition. Isolation and purification for such compounds were very difficult. We 
also attempted the coupling of crude amide with ureido fragments 44, 45 and 46 in different 
coupling conditions, but it resulted into no further reaction. 
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Scheme 3.5 
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Reagents and Conditions:  
a) BnBr, K2CO3,DMF, 0oC to RT, 3h and MeI, K2CO3,DMF, 0oC to RT, 3h b) DIBAL-H, 
DCM, -78oC, 2h c) PPh3, CBr4, DCM, 3h d) PPh3, Toluene, reflux, 5h d) N-Nonanal, LiH, 
MDS, THF, -78oC to RT, 5h. 
 
3.3.3 Synthesis of subunit A 
The linear synthesis of activated ureido fragment was achieved in 4 steps. This is shown in 
scheme 3.6 The benzyl protection of L-valine was carried out with PTSA and benzyl alcohol 
in toluene in 91% yield18. An unsymmetrical urea was synthesised between 41 and L-
phenylalanine methyl ester hydrochloride with the help of triphosgene at room temperature in 
85% yield19.The catalytic hydrogenation of compound 42 furnished the desired acid 43.The 
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acid 43 was activated by using different activating group like pentafluorophenol, p-
nitrophenol and acid chloride. 
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Reagents and Conditions: 
a) PTSA.H2O, Benzyl alcohol, Toluene, Reflux, 5h, 91% b)L-Phenylalanine methyl ester 
hydrochloride, Triphosgene, DIEA, DCM, RT, 2h,85% c) H2,Pd/C,EtOAC,RT,2h,80% d) 
Pentaflourophenol,DCC,EtOAc,RT,12h,66% e) P-nitrophenol, DCC, EtOAc, 12h, RT,90% f) 
Oxalyl chloride, DCM, DMF, 0oC to RT, 1h. 
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3.3.4 Attempts to remove the PMB group 
The fragment A was synthesised in good yield following a coupling protocol from 
commercially available amino acids, L-phenylalanine and L-valine. Conversely the synthesis 
of fragment B was found to be quite cumbersome. Several attempts were made for removal of 
PMB protecting group on different intermediats, but resulted into decomposition. Finally we 
succeeded to remove the PMB group from compounds 30 and 31 with the help of CAN20. 
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Once having succeeded to deprotect PMB group from compound 30, we planned to couple 
the protected ureido fragment 54. This is shown in scheme 3.7. The reduction of amino acid 
49 to amino alcohol 50, using LiBH4/TMSCl, proceeded cleanly and in high yield21. The 
ureido fragment between amino alcohol 50 and amino acid 24 was synthesised by using 
triphosgene, DIEA at RT. The alcoholic group of compound 51 was first protected as a TBS 
group with TBSCl and imidazole to give the corresponding ether 52 which was subjected to 
catalytic hydrogenation to give acid 53. Intial attempts of synthesis of pentafluoro-activated 
ester of 55 resulted into unstable compound. Later we succeeded to synthesise the para-
nitrophenol ester 54. The coupling between amide 48 and the activated ester 54 was carried 
out by using NaH in THF. Several attempts of reduction of this ester failed. 
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Scheme 3.7 
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Reagents and Conditions: 
a) LiBH4,TMSCl, THF,RT,16h,94% b) 24, DIEA, Triphosgene, DCM, RT,4 h,74% c) 
TBSCl, Imidazole, DCM, RT, 2h,84% d) H2, 10% Pd/C, EtOAc,RT,1h,92% e) PFP,DCC, 
EtOAc,RT,16 h f) p-Nitrophenol, DCC, EtOAc, RT, 16h,77% g) NaH,THF,RT, 30 min, 20% 
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We were particularly surprised by the failure of the reduction of the ester group with DIBAL-
H, a reaction which had been successful in other cases, e.g. on compound 30. Therefore we 
attempted to repeat the reaction on the analogue 58 of compound 55, where only the valine 
residue was attached to the pyrrolone ring, instead of both aminoacids (scheme 3.8). The 
NMR data shows that DIBAL-H reduction of compound 58 had reduced not only the ester, 
but also the CO group of the valine moiety, leading to compound 59. Further Swern oxidation 
of compound 59 proceeded only on primary alcohol, CHOH group of the valine residue 
remaining unoxidised. We decided anyway to proceed until the end of the sequence, to verify 
the feasibility of the synthetic approach. When the second aminoacid residue was coupled 
using triphosgene, this reagent also reacted with the hydroxyl and amino groups of 
compounds 62/63 to give the oxazolone 65/66. Subsequent catalytic hydrogenation in EtOAc 
of 65/66 afforded 67 in 50% yield. The core structure of compound 67 is new and a survey of 
the literature showed that compounds with this scaffold have never been isolated or 
synthesized before. Studies to evaluate its biological activity are underway. The NMR spectra 
of derivative 67 are  reported in the next pages (Figures 2, 3, 4). 
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Figure 2. 1H NMR of compound 67 
 71 
 
Figure 3 13C NMR of compound 67 
 72 
 
Figure 4. COSY spectrum of compound 67 
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To obtain Leopolic acid we turned back to compound 59. Both primary and secondary 
alcohols of compound 59 were oxidised with the help PCC to obtain aldehyde 88. The long 
chain was incorporated on 88 by Wittig olefination reaction with n-nonyl 
triphenylphoshonium bromide and BuLi at -78oC. The ureido fragment between amino acid 
64 and compound 90 was synthesised by using triphosgene at rt. This crude compound was 
subjected to catalytic hydrogenation affording final desired Leopolic acid A.   
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Reagents and Conditions: 
a) PFP, DCC, EtOAc, 0oC to RT, 1h, 91 % b) BuLi, THF, -78oC,1h,86% c) DIBAL-H, DCM, 
-78oC, 2h, 30% d) Oxalyl chloride, DMSO,THF, TEA, -78oC to 0oC, 2h, 60% e) N-Nonyl 
triphenylphoshonium bromide (61),THF,-78oC to 0oC, 2h, 73.80% f) DIEA, Triphosgene, 
DCM, RT,72h, 30% g) H2, Pd/C, EtOAc, RT, 2h, 50%. 
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Reagents and Conditions: 
a) PCC, DCM, 0oC to RT, 48h, 46% ; b) N-Nonyl triphenylphoshonium bromide (61), 
THF,-78oC to 0oC, 2h, 36% c)TFA, DCM, 0oC to RT d) 64, DIEA, Triphosgene, 
DCM, RT, 72h, 50%  e) H2,Pd/C, EtOAc, RT, 2h, 70%. 
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                                                     Part B 
              Approach towards the synthesis of a positional isomer of leopolic acid A 
The interesting structure of Leopolic acid A, with the ureido fragment linked to the pyrrolone 
core, and the antibacterial activity of some ureido compounds (see 3.2) induced us in the 
meantime to undergo the synthesis of a positional isomer of Leopolic acid A, i.e. a compound 
with the same side chains, but with a tetramic acid (instead of a 2,3-pyrrolidinedione) core, 
with the hope of increasing the antibacterial activity of tetramic acids (Figure 5). 
Figure 5  
General structure of 2,3 and 2,4-pyrrolidinediones 
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(tetramic acid)
  
3.4 Importance of Tetramic acid products  
          Natural products containing the tetramic acid structure (pyrrolidine-2,4-dione) are 
isolated from various terrestrial and marine organism; often they are metabolites originating 
from bacteria, fungi and assorted sponges. These structures can be characterised as simple 
heterocycles or more complex systems possibly containing long-chain fused polycyclic 
skeletons. This types of natural products often display wide ranging and potent biological 
activities including antibacterial, antiviral and antitumoral activities. Due to the intriguing 
structure and biological activity, tetramic acid containing products are attracting increasingly 
significant attention. Therefore this tetramic acid core is a key structure both for the synthesis 
of natural products as well as their unnatural analogues. 
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3.5 Natural compounds containing Tetramic acid core 
3.5.1 L-tenuazonic acid 
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The phytotoxin L-tenuazonic acid (72) was first isolated from the phytopathogenic fungus 
Alternaria alternate, the causative agent behind brown leaf spot of Eupatorium 
adenophorum22. The related analogue 3-acetyl-5-isopropyltetramic acid (3-AIPTA, 73) was 
isolated from the same strain by supplementing the culture with precursor L-valine23. In 
2004, 72 and 73 along with D-allo-tenuazonic acid (74) were re-discovered from two fungal 
strains A. brassicicola and A. raphani originating from pollen collected from beehives, which 
showed inhibitory activity against the causative agent of American foulbrood Paenibacillus 
larvae24. Further bioassays revealed that 74 accounts for the activity against P. larvae (MIC 
32 μg/mL), and displays activity comparable to the antibiotic oxytetracycline currently used 
to control American foulbrood25. Compounds 72 and 73 were also found to inhibit root and 
shoot growth rates and 73 displayed phytotoxicity against a wide range of plants. 
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3.5.2 Epicoccamide 
                                           
NO
OOHOO
OH
R1O
HO
OR2
n
Epicoccamide:R1-H,R2-H, n-1375
76 EpicoccamideB :R1-Ac,R2-H, n-13
77EpicoccamideC :R1-H,R2-Ac, n-13
78EpicoccamideD :R1-H,R2-H, n-15
 
Epicoccamide (75) was first isolated from cultures of the fungus Epicoccum purpurascens 
originating from the inner tissue of the jellyfish Aurelia aurita collected in the North Sea in 
200126. The compound was re-isolated as the major metabolite along with epicoccamides B–
D from the endofungal Epicoccum sp. associated with the tree fungus Pholiota squarrosa in 
200827. Epicoccamides consist of three biosynthetically distinct subunits: a ȕ -D-mannose, an 
aliphatic chain, and a tetramic acid moiety, which differ in their mannose substitution 
patterns and the length of their aliphatic chains. Epicoccamide (75) has thus far failed to show 
antimicrobial or cytotoxity activity although epicoccamides B–D (76-78) have demonstrated 
antiproliferative activity against cell lines L-929, K-562 and HeLa cell26-27. Epicoccamide D 
is the most active against HeLa (CC50＝17.0 μM), L-929 (GI50＝ 50.5 μM) and K-562 (GI50 ＝ 
33.3 μM). Furthermore, epicoccamide D induces morphogenesis and pigment formation in 
surface cultures of the fungus Phoma destructia at a concentration of 1.7 μM. 
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3.5.3 Reutericyclin 
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Reutericyclin (79), another tetramic acid was found to possess N-1 substitution with an α,ȕ 
unsaturated fatty acid, and was the first low molecular weight antibiotic isolated from the 
broth of lactic acid bacteria Lactobacillus reuteri LTH2584 originating from an industrial 
sourdough SER28. Reutericyclin has shown potent activity against a broad range of Gram-
positive bacteria and drug-resistant strains with the values of MICs in the range 0.08 to 6.25 
mg mL-1. However, thus far, reutericyclin has failed to inhibit the growth of yeast, fungi and 
Gram-negative bacteria. Differences in the activity against L. sanfranciscensis between 
natural reutericyclin (MIC＝0.10 mg mL-1) and synthetic racemic reutericyclin (MIC＝0.75 mg 
mL-1) indicated that stereochemistry is vital to the compounds bioactivity29. 
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3.5.4 BelamideA 
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Belamide A (80), a highly methylated structural analogue of dolastatin was isolated from the 
Panamanian marine cyanobacterium Symploca Sp30. Compound 80 was found to be cytotoxic 
to MCF7 and HCT-116 cell lines with IC50 values of 1.6 μM and 0.74 μM, respectively. In 
addition, 80 showed classic microtubule depolymerizing effects toward A-10 cells at 20 
μM30. 
3.5.5 Eliamid  
                                  
O
N
O
O
O
81
 
Eliamid (81) was isolated from two strains: ambruticins producer Sorangium cellulosum So 
ce439 (DSMZ 11529) and soraphen producer S. cellulosum So ce24131. Eliamid was found to 
exert potent activity against a panel of transformed cell lines with the IC50 values in the 
range 0.5–30.0 ng ML-1. In addition, 81 showed cytotoxic activity against brine shrimp 
Artemia salina at 0.2–0.3 μg/mL, lethal activity against soil nematodes (Panagrellus spec.) at 
5 μg/mL, and moderate inhibitory activity against fungi and yeast in agar diffusion assays 
(ranging from 15–22 mm zone at 20 μg per disk). The mode of action was determined by 
examining the effects of 81 on the mitochondrial respiratory chain. Compound 81 was found 
 81 
to strongly inhibit NADH oxidation in beef heart submitochondrial particles (SMP) with an 
IC50 of 8 ng/mL and differential spectroscopy experiments with beef SMP indicated that 81 is 
a potent inhibitor of complex I (NADH-ubiquinone oxidoreductase) within the eukaryotic 
respiratory chain. 
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3.6 Approach towards the synthesis of a positional isomer of Leopolic Acid A 
3.6.1 Retrosynthetic Approach 
Our initial retrosynthetic analysis is outlined in scheme 3.9. We envisioned that an isomer of 
Leopolic acid A containing a tetramic acid core could be constructed by a convergent 
synthetic strategy. Our strategy for the synthesis of the isomer of Leopolic acid A was based 
on the coupling of two domains: Ureido fragment 82 and Tetramic core 83. 
 83 
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3.6.2 Synthesis of Tetramic core 83 
N-(4-methoxybenzyl)glycine ethyl ester 86 was synthesized from ethyl bromoacetate and p-
methoxybenzylamine32. The amine 86 was converted into N-dodecanoyl-(4-
methoxybenzylamino)acetate 87 with the help of CHCl3 and TEA33. The Dieckmann 
 84 
condensation of 87 was carried out in different conditions but resulted into no reaction. The 
synthesis of Tetramic core 83 is shown in scheme 3.11. N-(4-methoxybenzyl)glycine ethyl 
ester 86 was converted into amide 88 by condensation with benzyl malonyl chloride with the 
help of DCC , DMAP in 83% yield. Tetrabutylammonium fluoride in ether at room 
temperature induced cyclisation and formation of an enolate which was subsequently treated 
with 1-iododecane to afford 8934. PMB deprotection of 89 with ceric ammonium nitrate 
afforded amide 90. The coupling between amide 91 and pentafluoro-activated ureido 
fragment 44 by using BuLi in dry THF afforded compound 91. Now we are trying to remove 
the benzyl ester with hydrogenolysis and subsequentally decarboxylation of the acid . 
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Reagent and Conditions: 
a) TEA, THF, 0oC to RT, 2.5h, 87%; b) Dodecanoyl chloride, TEA, CHCl3, 83% 
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Reagent and Conditions: 
a) TEA, THF, 0oC to RT, 2.5h, 87%;  b) DCC, DMAP, DCM, 0oC to RT, 24h, 83% c) 
TBAF,Et2O,THF,1-Iododecane, RT, 24h 30%  d) CAN, ACN:Water (3:1), 0oC to RT, 1h, 
66%. 
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3.7 Experimental section 
General Experimental methods 
All reagents and solvents were reagent grade or were purified by standard methods before 
use. Melting points were determined in open capillaries and are uncorrected. NMR spectra 
were recorded in CDCl3 (where not otherwise stated) at 300 MHz. Chemical shifts ( values) 
and coupling constants (J values) are given in ppm and Hz, respectively. Solvents were 
routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and ether (Et2O) were 
obtained by distillation from sodium-benzophenone ketyl; dry methylene chloride was 
obtained by distillation from phosphorus pentoxide. All reactions requiring anhydrous 
conditions were performed under a positive nitrogen flow, and all glassware were oven dried 
and/or flame dried. Isolation and purification of the compounds were performed by flash 
column chromatography on silica gel 60 (230-400 mesh). Analytical thin-layer 
chromatography (TLC) was conducted on Fluka TLC plates (silica gel 60 F254, aluminum 
foil).  
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                            Ethyl 3-(4-methoxybenzylamino)propanoate 
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  A mixture of 4-methoxybenzylamine (10 g, 72.90 mmol) in ethanol (100 mL) and ethyl 
acrylate (6.27 g, 72.90 mmol) was stirred at room temperature for 12 h. After completion of 
reaction, the mixture was concentrated in vacuo to give product 8 (16.88 g, 98%) 
Physical appearance- Pale yellow liquid 
Rf 0.5 (EtOAc/ Hexane 6:2) 
1H-NMR (CDCl3) : 7.23 (2H, d, J = 8.5 Hz); 6.85 (2H, d, J = 8.5 Hz); 4.13 (2H, q, J = 7.2 
Hz); 3.80 (3H, s); 3.74 (2H, s); 2.88 (2H, t, J = 6.6 Hz); 2.52 (2H, t, J = 6.6 Hz); 1.25 (3H, t; J 
= 7.2 Hz).  
Anal. calcd for C13H19NO3: C, 65.80; H, 8.07; N, 5.90. Found: 66.01; H, 8.03; N, 5.92. 
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                                  Ethyl 3-(benzylamino)propanoate 
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  A mixture of benzylamine (10 g, 93.35 mmol) in ethanol (100 mL) and ethyl acrylate (6.27 
g, 93.35 mmol) was stirred at room temperature for 12 h. After completion of reaction, the 
mixture was concentrated in vacuo to give product 8 (18 g, 94%) 
Physical appearance- White viscous liquid 
Rf 0.5 (EtOAc/ Hexane 6:2) 
1H-NMR (CDCl3) : 7.40-7.32 (3H, m); 7.38-7.25 (2H, m); 2.16 (2H, t, J = 7.3 Hz); 3.83 
(2H, s); 2.95 (2H, t, J = 7.2 Hz); 2.53 (2H, t, J = 7.2 Hz); 1.23 (3H, t, J = 7.3 Hz). 
 89 
                  Tert-butyl 2-(ethoxycarbonyl)ethyl-4-methoxybenzylcarbamate 
                                                         
N O
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To the stirred solution of compound 8 (2.0g, 8.4mmol) in dry DCM were added TEA (2.2 g, 
10.11mmol) and (Boc)2O (1.8g, 1.8 mmol) at 0oC, then the solution was allowed to stir for 5h 
at room temperature. After the completion of reaction, it was diluted with EtOAc and washed 
with water and brine solution. The organic layer was dried over anhydrous Na2SO4, filtered 
and concentrated. The crude product was purified by flash column chromatography (10% 
EtOAc/Hexane) to afford 10 (2.4 g, 85%) 
Physical appearance- White viscous liquid 
Rf 0.7 (EtOAc/ Hexane 2:8) 
1H-NMR (CDCl3) : 7.16 (2H, m); 6.85 (2H, d, J = 8.5 Hz); 4.38 (2H, s); 4.10 (2H, q, J = 7.0 
Hz); 3.80 (3H, s); 3.46 (2H, m); 2.48 (2H, m); 1.44 (9H, s); 1.24 (3H, t, J = 7.0 Hz). 
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                                      Ethyl 3-(dibenzylamino)propanoate 
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To the stirred solution of compound 9 (2.0g, 9.6mmol) in dry DMF (40mL) was added 
K2CO3 (8.0 g, 57.93 mmol) at 0oC and the solution was stirred for 10 min, then BnBr (4.95g, 
28.96 mmol) was added. Then reaction was allowed to stir for 24h at room temperature. After 
the completion, the reaction mixture was concentrated in vacuo. The crude product was 
purified by flash column chromatography (04% EtOAc/Hexane) to afford 11 (2.5 g, 89%) 
Physical appearance- White viscous liquid 
Rf 0.5 (EtOAc/ Hexane 1:9) 
1H-NMR (CDCl3) : 7.42-7.15 (10H, m); 4.08 (2H, q, J = 7.3 Hz); 3.58 (4H, s); 2.81 (2H, t, J 
= 7.2 Hz); 2.49 (2H, t, J = 7.2 Hz); 1.20 (3H, t, J = 7.3 Hz). 
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           Tert-butyl 2-(ethoxycarbonyl)dodecyl- 4-methoxybenzylcarbamate 
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To the stirred solution of compound 10 (1.0g, 2.9 mmol) in dry THF (20mL) was added a 
1.8M solution of LDA (4.1mL, 7.4 mmol) at -78oC. After 45 min HMPA (3.1g, 17.78 mmol) 
was added and the solution was stirred for 20 min at same temperature. After addition of neat 
1-iododecane (3.9 g, 14.81 mmol) at - 78oC, the solution was allowed to raise the temperature 
and stirred for 24 at RT. After the completion of reaction, the mixture was quenched with 
sat.NH4Cl and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(6% EtOAc/Hexane) to afford 12 (1.0 g, 71%) 
Physical appearance- Colorless viscous liquid 
Rf 0.5 (EtOAc/ Hexane 1:9) 
1H-NMR (CDCl3) : 7.16 (2H, m); 6.86 (2H, d, J = 8.2 Hz); 4.14 (2H, q, J = 6.7 Hz); 3.81 
(3H, s); 3.30 (2H, m); 2.78 (1H, m); 1.65-1.20 (30H, m); 0.89 (3H, t, J = 6.7 Hz). 
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                             Ethyl 2-((dibenzylamino)methyl)dodecanoate 
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To the stirred solution of compound 11 (1.0g, 3.36mmol) in dry THF (20 mL) was added a 
1.8M solution of LDA (15.15mL, 8.4 mmol) at - 78oC. After 45 min HMPA (3.6 g, 20.20 
mmol) was added and the solution was stirred for 20 min at same temperature. After addition 
of neat 1-iododecane (4.5 g, 16.83 mmol) at - 78oC, the solution was allowed to raise the 
temperature and stirred for 24 at RT. After the completion of reaction, the mixture was 
quenched with sat.NH4Cl and extracted with EtOAc. The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated. The crude product was purified by flash 
column chromatography (4% EtOAc/Hexane) to afford 13 (1.2 g, 81%) 
Physical appearance-White solid 
Rf 0.5 (EtOAc/ Hexane 1:9) 
1H-NMR (CDCl3) : 7.37-7.07 (10H, m); 4.23 (2H, m); 3.68 (2H, m); 3.44-3.39 (2H, m); 
2.65 (1H, m); 2.48-2.30 (4H, m); 1.60-1.10 (21H, m); 0.88 (3H, t, J = 6.7 Hz). 
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                        Ethyl 2-((4-methoxybenzylamino)methyl)dodecanoate 
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To the stirred solution of compound 12 (0.5g, 1.0 mmol) in DCM (10 mL) was added TFA 
(0.5 mL) at 0oC and then the solution was allowed to stir for 2h at RT. After the completion 
of reaction, the mixture was evaporated under reduced pressure. The crude was basified with 
sat. NaHCO3, extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(50% EtOAc/Hexane) to afford 14 (0.3g, 76%) 
Physical appearance- Colorless viscous liquid. 
Rf 0.5 (EtOAc/ Hexane 1:9) 
1H-NMR (CDCl3) : 7.26 (2H, d, J = 8.5 Hz); 6.87 (2H, d, J = 8.5 Hz); 4.17 (2H, q, J = 6.7 
Hz); 3.88 (3H, s); 3.80-3.70 (2H, m); 2.89 (1H, m); 2.80-2.61 (12H, m); 2.01 (1H, brs); 1.65-
1.18 (21H, m); 0.89 (3H, t, J = 6.7 Hz). 
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                              Ethyl 2-((benzylamino)methyl)dodecanoate 
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To the stirred solution of 13 (0.2 g, 0.4 mmol) in ACN:Water (3:1) was added cerium 
ammonium nitrate (0.6 g, 1.1mmol) at 0°C, then the mixture was allowed to stir for 1h at 
room temperature. After the completion of reaction, the mixture was diluted with EtOAc and 
washed with water and brine solution. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(50% EtOAc/Hexane) to afford 14 (0.11 g, 70%) 
Physical appearance Yellowish viscous liquid. 
Rf  0.3 (EtOAc/Hexane 5:5) 
MP  160°C   
1H NMR (CDCl3) : 7.41-7.14 (5H, m); 4.15 (2H, q, J = 7.2 Hz); 3.85-3.72 (2H, m); 2.87 
(1H, dd, J = 8.9, 11.7 Hz); 2.69 (1H, dd, J = 4.7, 11.7 Hz); 2.58 (1H, m); 1.75 (2H, m); 1.65-
1.20 (19H, m); 0.87 (3H, t, J = 7.2 Hz). 
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    Ethyl 1-(4-methoxybenzyl)-2,5-dihydro-4-hydroxy-5-oxo-1H-pyrrole-3-carboxylate 
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A mixture of ethyl 3-(4-methoxybenzylamino)propanoate 8 (15 g, 63.21 mmol), NaOEt (2.1 
g, 94.21 mmol) and diethyl oxalate (11.08 g,75.85 mmol) was refluxed for 3h. After removal 
of all the volatiles under vacuum the solid residue obtained was dissolved in boiling water 
and filtered while hot. Neutralization of the filtrate with 2 N HCl gave a precipitate, which 
was filtered, washed with water and dried under vacuum to give the  desired product 16 (18 
g, 83%) 
Physical appearance- white solid 
Rf 0.5(MeOH/DCM 1:9) 
MP  133°C   
1H NMR (CDCl3) : 7.18 (2H, d, J = 8.7 Hz); 6.86 (2H, d, J = 8.7 Hz); 4.60 (2H, s); 4.26 
(2H, s); 3.83 (2H, s); 3.79 (3H, s); 1.29 (3H, t, J = 7.0 Hz).  
Anal. calcd for C15H17NO5: C, 61.85; H, 5.88; N, 4.81. Found: C, 61.60; H, 5.90; N, 4.82. 
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            Ethyl 1-benzyl-2,5-dihydro-4-hydroxy-5-oxo-1H-pyrrole-3-carboxylate 
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A mixture of Ethyl 3-(benzylamino)propanoate 9 (2.0 g, 9.6 mmol), NaOEt (0.98 g, 14.48 
mmol) and diethyl oxalate (1.6 g, 11.58 mmol) was refluxed for 3h. Removed all the volatiles 
under vacuum the solid residue obtained was dissolved in boiling water and filtered while 
hot. Neutralization of the filtrate with 2 N HCl gave precipitate, which was filtered, washed 
well with water and dried in vacuum to give  desired product 17 (2.0 g, 80%) 
Physical appearance- white solid 
Rf 0.5 (MeOH/DCM 1:9) 
1H NMR (CDCl3) : 7.42-7.15 (5H, s); 4.67 (2H, s); 4.26 (2H, q, J = 7.2 Hz); 3.86 (2H, s); 
1.29 (3H, t, J = 7.2 Hz). 
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4-(tert-Butyl-dimethyl-silanyloxy)-1-(4-methoxy-benzyl)-5-oxo-2,5-dihydro-1H-pyrrole-
3-carboxylic acid ethyl ester 
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To the solution of 16 (5 g, 51.49 mmol) in dry DCM (50 mL), imidazole (2.33 g, 34.32 
mmol) was added portionwise at 0°C and mixture was stirred for 10 min. TBSCl (5.1 g, 
34.32 mmol) was added at 0°C  and resulting reaction mixture was stirred 6h at RT. The 
organic solvent was removed under reduced pressure .The residue was dissolved in EtOAc  
and washed with water and brine solution. The organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated. The crude product was purified by flash column 
chromatography (12% EtOAc/Hexane) to afford 18 (6 g, 86%) 
Physical appearance- White solid 
Rf 0.5(EtOAc/Hexane 2:8) 
MP  85°C   
1H NMR (CDCl3) : 7.15 (2H, d, J = 8.7 Hz); 6.81 (2H, d, J = 8.7 Hz); 4.52 (2H, s); 4.22 
(2H, q, J = 7.0 Hz); 4.11 (2H, q, J = 7.0 Hz, 2nd rotamer); 3.83 (2H, s); 3.78 (3H, s); 1.28 (3H, 
t, J = 7.0 Hz); 1.24 (3H, t, J = 7.0 Hz, 2nd rotamer); 0.99 (9H, s); 0.35 (6H, s).  
Anal. calcd for C21H31NO5Si: C, 62.19; H, 7.70; N, 3.45. Found: C, 62.41; H, 7.66; N, 3.46. 
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1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic 
acid ethyl ester 
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To the solution of 17 (5 g, 19.29 mmol) in dry DCM (50 mL) , imidazole (2.6 g, 38.59 mmol) 
was added portionwise at 0°C and mixture was stirred for 10 min. TBSCl (5.7 g,  38.59 
mmol) was added at 0°C  and resulting reaction mixture was 6h at RT. The organic solvent 
was removed under reduced pressure .The residue was dissolved in EtOAc  and washed with 
water and brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated .The crude product was purified by flash column chromatography (12% 
EtOAc/Hexane) to afford 19 (5.0g, 69%) 
Physical appearance White solid 
Rf 0.5(EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.42-7.12 (5H, m); 4.62 (2H, s); 4.23 (2H, q, J = 7.2 Hz); 3.87 (2H, s); 
1.29 (3H, t, J = 7.2 Hz); 1.01 (9H, s); 0.37 (6H, s). 
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  3-(tert-Butyl-dimethyl-silanyloxy)-4-hydroxymethyl-1-(4-methoxy-benzyl)-1,5-dihydro-
pyrrol-2-one 
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To the solution of 18 (4 g, 9.8mmol)  in dry DCM (40 mL) was added  diisobutylaluminium 
hydride (1.0 M in DCM, 19.72 mL, 19.72 mmol) at -78oC and the solution was stirred for 1h 
at the same temperature. After completion of reaction, the mixture was quenched with sat. 
Rochelle salt and EtOAc were added, and stirring was continued for 10 min. The aqueous 
phase was extracted three times with EtOAc. The organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated. The crude product was purified by flash column 
chromatography (40% EtOAc/Hexane) to afford 20 (2.5 g, 72%) 
Physical appearance Off white solid 
Rf 0.5(EtOAc/Hexane 4:6) 
MP  148°C   
1H NMR (CDCl3) : 7.16 (2H, d, J = 8.5 Hz); 6.84 (2H, d, J = 8.5 Hz); 4.52 (2H, s); 4.41 
(2H, s); 3.79 (3H, s); 3.70 (2H, s); 0.96 (9H, s); 0.29 (6H, s).  
Anal. calcd for C19H29NO4Si: C, 62.78; H, 8.04; N, 3.85. Found: C, 62.55; H, 8.06; N, 3.86. 
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1-Benzyl-3-(tert-butyl-dimethyl-silanyloxy)-4-hydroxymethyl-1,5-dihydro-pyrrol-2-one 
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To the solution of 19 (2.5 g, 6.6 mmol)  in dry DCM (40mL) was added  
Diisobutylaluminium hydride (1.0 M in DCM, 13.3 mL, 13.32 mmol) at -78oC and the 
solution was stirred for 1h at same temperature. After completion of reaction, the mixture was 
quenched with sat. Rochelle salt and EtOAc was added, then stirring was continued  for 10 
min. The aqueous phase was extracted three times with EtOAc. The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by flash 
column chromatography (40% EtOAc/Hexane) to afford 21 (2.0g, 90%) 
Physical appearance Off white solid 
Rf 0.5 (EtOAc/Hexane 4:6) 
1H NMR (CDCl3) : 7.46-7.13 (5H, m); 4.61 (2H, s); 4.44 (2H, s); 3.74 (2H, s); 0.99 (9H, s); 
0.30 (6H, s). 
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4-Bromomethyl-3-(tert-butyl-dimethyl-silanyloxy)-1-(4-methoxy-benzyl)-1,5-dihydro-
pyrrol-2-one 
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To the solution of 20 (2 g, 5.5 mmol) in dry DCM (40mL) were added PPh3 (2.8 g, 11mmol) 
and CBr4 (3.6 g, 11 mmol) at 0°C. Then reaction was allowed to stir for 3 h at RT. After 
completion of reaction, the mixture was evaporated in vacuo. The crude product was purified 
by flash column chromatography (8% EtOAc/Hexane) to afford 22 (2 g, 87%) 
Physical appearance Colorless viscous liquid. 
Rf  0.7 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.16 (2H, d, J = 8.4 Hz); 6.86 (2H, d, J = 8.4 Hz); 4.53 (2H, s); 4.17 
(2H, s); 3.79 (3H, s); 3.75 (2H, s); 0.99 (9H, s); 0.32 (6H, s).  
Anal. calcd for C19H28BrNO3Si: C, 53.69; H, 6.58; N, 3.28. Found: C, 53.52; H, 6.62; N, 
3.27. 
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1-Benzyl-4-bromomethyl-3-(tert-butyl-dimethyl-silanyloxy)-1,5-dihydro-pyrrol-2-one 
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To the solution of 21 (1.0g, 2.9 mmol) in dry DCM (40mL) were added PPh3 (1.5g, 5.9 
mmol) and CBr4 (1.9g, 5.9 mmol) at 0°C, then the reaction was allowed to stir for 3 h at RT. 
After completion of reaction, the mixture was evaporated in vacuo. The crude product was 
purified by flash column chromatography (8% EtOAc/Hexane) to afford 23 (0.8g, 72%) 
Physical appearance Yellowish Viscous liquid. 
Rf 0.7 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.43-7.14 (5H, m); 4.60 (2H, s); 4.19 (2H, s); 3.78 (2H, s); 1.00 (9H, s); 
0.33 (6H, s). 
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N
O
O
Ph3P
O
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24
Br
 
To the solution of 22 (2 g, 4.7 mmol) in dry toluene (40mL) was added PPh3 (1.84 g, 7mmol) 
and the mixture was refluxed for 6 h. After cooling toluene was decanted, the solid was 
triturated with diethyl ether to give the desired phosphonium bromide 24 (2 g, 61%) 
Physical appearance White solid 
MP 220°C   
Rf  0.5 (MeOH/DCM  1:9) 
1H NMR (CDCl3) : 7.86-7.38 (15H, m); 6.97 (2H, d, J = 7.9 Hz); 6.76 (2H, d, J = 7.9 Hz); 
5.27 (2H, d, J = 15.9 Hz); 4.37 (2H, s); 3.81 (3H, s); 3.53 (2H, s); 0.76 (9H, s); 0.22 (6H, s). 
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N
O
O
Ph3P
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To the solution of 23 (1.0 g, 2.5 mmol) in dry toluene (10 mL) was added PPh3 (0.9 g, 3.7 
mmol) and the mixture was refluxed for 6 h. After cooling toluene was decanted, the solid 
was triturated with diethyl ether to give the desired phosphonium bromide 25 (1.4g, 90%) 
Physical appearance White solid 
Rf 0.5 (MeOH/DCM  1:9) 
1H NMR (CDCl3) : 7.86-7.65 (12H, m); 7.64-7.51 (8H, m); 5.40 (2H, d, J = 15.3 Hz); 4.45 
(2H, s); 3.37 (2H, s); 0.76 (9H, s); 0.21 (6H, s). 
 105 
3-(tert-Butyl-dimethyl-silanyloxy)-4-dec-1-enyl-1-(4-methoxy-benzyl)-1,5-dihydro-
pyrrol-2-one 
                         
N
O
O
O
Si
26  
 
To the solution of 24 (1.5 g, 2.1 mmol) was added LiHMDS (1 M in THF, 3.2 mL, 3.2mmol) 
at -78oC dropwise under nitrogen atmosphere. After stirring for 30 min, it was added a 
solution of n-nonanal in THF. Then reaction was allowed to warm up and stirred further for 5 
h at RT. After the completion of reaction, mixture was quenched with sat.NH4Cl and 
extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (10% 
EtOAc/Hexane) to afford 26 (0.9 g, 88%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 1:9) 
 
1H NMR (CDCl3) : 7.19 (2H, d, J = 8.2 Hz); 6.88 (2H, d, J = 8.2 Hz); 6.28 (1H, d, J = 11.9 
Hz); 5.49 (1H, m); 4.58 (2H, s); 3.93 (2H, s); 3.81 (3H, s); 2.07 (2H, m); 1.46-1.18 (12H, m); 
1.00 (9H, s); 0.89 (3H, t, J = 7.0 Hz); 0.22 (6H, s). 
 106 
1-Benzyl-3-(tert-butyl-dimethyl-silanyloxy)-4-dec-1-enyl-1,5-dihydro-pyrrol-2-one 
                                
N
O
O Si
27  
To the solution of 25 (1.0 g, 1.5 mmol) was added LiHMDS (1 M in THF, 1.5 mL, 1.5mmol) 
at -78oC dropwise under nitrogen atmosphere. After stirring for 30 min, it was added a 
solution of n-nonanal (0.129 g, 0.9 mmol) in THF. Then reaction was allowed to warm up 
and stirred further for 5 h at RT. After the completion of reaction, the mixture was quenched 
with sat.NH4Cl and extracted with EtOAc. The organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated. The crude product was purified by flash column 
chromatography (10% EtOAc/Hexane) to afford 27 (0.5g, 74%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 1:9) 
 
1H NMR (CDCl3) : 7.41-7.16 (5H, m); 6.27 (1H, d, J = 11.3 Hz); 5.49 (1H, m); 4.62 (2H, 
s); 3.93 (2H, s); 2.05 (2H, m); 1.56-1.10 (12H, m); 1.03 (9H, s); 0.87 (3H, t, J = 6.9 Hz); 0.30 
(6H, s). 
 
 
 
 
 107 
3-(tert-Butyl-dimethyl-silanyloxy)-4-decyl-1-(4-methoxy-benzyl)-1,5-dihydro-pyrrol-2-
one 
                    
N
O
O
O
Si
28  
 
To the solution of 26 (0.5 g, 1mmol) in EtOAc (20mL) was added a catalytic amount of 
10%Pd/C. The reaction mixture was stirred for 1h at RT under hydrogen atmosphere. After 
the completion of reaction, the mixture was filtered through a celite bed and it was washed 
with EtOAc three times. EtOAc was concentrated under vacuo. The crude product was 
purified by flash column chromatography (10% EtOAc/Hexane) to afford 28 (0.45 g, 89%) 
Physical appearance White viscous liquid 
Rf 0.5(EtOAc/Hexane 1:9) 
 
1H NMR (CDCl3) : 7.16 (2H, d, J = 8.5 Hz); 6.86 (2H, d, J = 8.5 Hz); 4.53 (2H, s); 3.81 
(3H, s); 3.54 (2H, s); 2.27 (2H, t, J = 8.2 Hz); 1.56-1.12 (16H, m); 0.99 (9H, s); 0.89 (3H, t, J 
= 7.0 Hz); 0.22 (6H, s).  
Anal. calcd for C28H47NO3Si: C, 70.98; H, 10.00; N, 2.96. Found: 701.20; H, 10.03; N, 2.95. 
 108 
Ethyl 1-(4-methoxybenzyl)-4-(benzyloxy)-2,5-dihydro-5-oxo-1H-pyrrole-3-carboxylate 
                                                       
N
O
O
OO
O
30
 
To the stirred solution of 16 (15 g, 51 mmol) in dry DMF (150mL) was added anhydrous 
K2CO3 (21 g, 154 mmol) at 0°C and the solution was stirred for 15 min, then was added BnBr 
(9.6 g, 56 mmol). The reaction mixture was allowed to warm up and stirred further for 1h. 
After completion of reaction, the mixture was diluted with EtOAc and washed with cold 
brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (25% 
EtOAc/Hexane) to afford 30 (10 g, 50%) 
Physical appearance White solid 
Rf 0.5 (EtOAc/Hexane 3:7) 
MP 72°C   
1H NMR (CDCl3) : 7.54-7.45 (2H, m); 7.42-7.31 (3H, m); 7.18 (2H, d, J = 8.5 Hz); 6.88 
(2H, d, J = 8.5 Hz); 5.82 (2H, s); 4.57 (2H, s); 4.24 (2H, q, J = 7.0 Hz); 3.86 (2H, s); 3.82 
(3H, s); 1.30 (3H, t, J = 7.0 Hz).  
Anal. calcd for C22H23NO5: C, 69.28; H, 6.08; N, 3.67. Found: C, 69.05; H, 6.10; N, 3.66. 
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    Ethyl 1-(4-methoxybenzyl)-2,5-dihydro-4-methoxy-5-oxo-1H-pyrrole-3-carboxylate 
                                                    
N
O
O
OO
O
31
 
To the stirred solution of 16 (1.0 g, 3.4 mmol) in dry DMF (20 mL) was added anhydrous 
K2CO3 (1.4 g, 10 mmol) at 0°C and the resulting solution was stirred for 15 min, then was 
added BnBr (0.58 g, 4.1 mmol) . The reaction mixture was allowed to warm up and stirred 
further for 1h. After completion of reaction, the mixture was diluted with EtOAc and  washed 
with cold brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (30% 
EtOAc/Hexane) to afford 31 (0.65 g, 62%) 
Physical appearance White solid 
Rf 0.5 (EtOAc/Hexane 5:5)  
1H NMR (CDCl3) : 7.20 (2H, d, J = 8.5 Hz); 6.88 (2H, d, J = 8.5 Hz); 4.58 (2H, s); 4.34 
(3H, s); 4.22 (2H, q, J = 7.0 Hz); 3.86 (2H, s); 3.81 (3H, s); 1.29 (3H, t, J = 7.0 Hz). Anal. 
calcd for C16H19NO5: C, 62.94; H, 6.27; N, 4.59. Found: C, 62.70; H, 6.26; N, 4.60. 
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      1-(4-methoxybenzyl)-3-(benzyloxy)-4-(hydroxymethyl)-1H-pyrrol-2(5H)-one                                           
                                                            
N
O
O
O
HO
32
 
 
To the solution of 30 (5 g,  13 mmol) in dry DCM (50mL) was added  diisobutylaluminium 
hydride (1.0 M in DCM, 26 mL, 26 mmol) at -78oC and the solution was stirred for 1h at the 
same temperature. After completion of reaction, the mixture was quenched with sat. 
Rochellesalt and EtOAc was added, stirred for 10 min. The aqueous phase was extracted 
three times with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (40% 
EtOAc/Hexane) to afford 32 (2.5 g, 56%) 
Physical appearance White viscous liquid  
Rf 0.5 (EtOAc/Hexane 4:6) 
1H NMR (CDCl3)  : 7.45-7.33 (5H, m); 7.18 (2H, d, J = 8.5 Hz); 6.88 (2H, d, J = 8.5 Hz); 
5.41 (2H, s); 4.57 (2H, s); 3.82 (3H, s); 3.62 (2H, s).  
Anal. calcd for C20H21NO4: C, 70.78; H, 6.24; N, 4.13. Found: C, 71.00; H, 6.23; N, 4.12. 
 
 
 
       
 
 111 
       1-(4-methoxybenzyl)-4-(hydroxymethyl)-3-methoxy-1H-pyrrol-2(5H)-one 
                                                     
N
O
O
O
HO
33
 
To the stirred solution of 31 (0.5 g, 1.6 mmol) in EtOH was added NaBH4 (0.18 g, 4.9 mmol) 
at 0oC and the solution was allowed to stir for 5h at RT. After the completion of reaction, the 
mixture was evaporated by rotavapor and quenched with sat.NH4Cl, extracted with EtOAc. 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude 
product was purified by flash column chromatography (40% EtOAc/Hexane) to afford 33 
(0.2 g, 50%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 6:4) 
1H NMR (CDCl3) : 7.18 (2H, d, J = 8.8 Hz); 6.86 (2H, d, J = 8.8 Hz); 4.53 (2H, s); 4.46 
(2H, s); 4.03 (3H, s); 3.80 (3H, s); 3.72 (2H, s). 
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          1-(4-methoxybenzyl)-3-(benzyloxy)-4-(bromomethyl)-1H-pyrrol-2(5H)-one 
                                                           
N
O
O
O
Br
34
 
To the solution of 32 (2 g, 5.8 mmol) were added PPh3 (3.1 g, 11.79 mmol) and CBr4 (3.9 g, 
11.79 mmol) at 0°C. The reaction was allowed to stir for 3h at RT. After completion of 
reaction, the mixture was evaporated in vacuo. The crude product was purified by flash 
column chromatography (22% EtOAc/Hexane) to afford 34 (1.2 g, 52%) 
Physical appearance Yellowish liquid 
Rf  0.6 (EtOAc/Hexane 3:7) 
1H NMR (CDCl3) : 7.48-7.30 (5H, m); 7.18 (2H, d, J = 8.5 Hz); 6.88 (2H, d, J = 8.5 Hz); 
5.53 (2H, s); 4.56 (2H, s); 4.11 (2H, s); 3.82 (3H, s); 3.76 (2H, s). 
 Anal. calcd for C20H20BrNO3: C, 59.71; H, 5.01; N, 3.48. Found: C, 59.90; H, 5.00; N, 3.49. 
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           1-(4-methoxybenzyl)-4-(bromomethyl)-3-methoxy-1H-pyrrol-2(5H)-one 
                                                  
N
O
O
O
Br
35
 
To the solution of 33 (0.3g, 1.1mmol) were added PPh3 (0.57g, 2.2mmol) and CBr4 (0.75g, 
2.2mmol) at 0°C.The reaction was allowed to stir for 3 h at RT. After completion of reaction, 
the mixture was evaporated in vacuo. The crude product was purified by flash column 
chromatography (22% EtOAc/Hexane) to afford 35 (0.15g, 40%) 
Physical appearance White viscous liquid. 
Rf  0.6 (EtOAc/Hexane 3:7) 
1H NMR (CDCl3) : 7.19 (2H, d, J = 8.8 Hz); 6.88 (2H, d, J = 8.8 Hz); 4.55 (2H, s); 4.22 
(2H, s); 4.16 (3H, s); 3.81 (3H, s); 3.77 (2H, s). 
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To the solution of 34 (1 g, 2.4 mmol) in dry toluene (10 mL) was added PPh3 (1 g, 3.7 mmol) 
and the mixture was refluxed for 6 h. After cooling toluene was decanted, the solid was 
triturated to give the desired phosphonium bromide 36 (1.2 g, 75%) 
Physical appearance   White solid 
MP    167°C   
Rf   0.5 (MeOH/DCM  1:9) 
1H NMR (CDCl3) (8H, m); 7.57-7.42 (6H, m); 7.41-7.37 (3H, m); 7.25-7.14 
(3H, m); 7.06 (2H, m, J = 8.5 Hz); 6.28 (2H, d, J = 8.5 hz); 5.33 (2H, s); 5.21 (2H, d, J = 15.3 
Hz); 4.37 (2H, s); 3.84 (3H, s); 3.58 (2H, d, J = 4.0 Hz). 
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N
O
O
O
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To the solution of 35 (1g, 3.0 mmol) in dry toluene (10 mL) was added PPh3 (2.4g, 9.1 mmol) 
the mixture was refluxed for 6 h. After cooling toluene was decanted, the solid was triturated 
to give the desired phosphonium bromide 37 (1.26 g, 70%) 
Physical appearance   White solid 
Rf   0.5 (MeOH/DCM 1:9) 
1H NMR (CDCl3) : 7.87-7.67 (9H, m); 7.65-7.52 (6H, m); 7.02 (2H, d, J = 8.5 Hz); 6.79 
(2H, d, J = 8.5 Hz); 5.24 (2H, d, J = 15.4 Hz); 4.35 (2H, s); 3.81 (3H, s); 3.80 (3H, s); 3.56 
(2H, d, J = 3.4 Hz). 
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      1-(4-methoxybenzyl)-3-(benzyloxy)-4-((E)-dec-1-enyl)-1H-pyrrol-2(5H)-one                          
                                            
N
O
O
O
38
 
To the solution of 36 (1 g, 1.5mmol) was added LiHMDS (1 M in THF, 1.5 mL, 1.5 mmol) at 
-78oC dropwise under nitrogen atmosphere. After stirring for 30 min, added solution of n-
nonanal (0.25 g, 1.8 mmol) in THF. Then reaction was allowed to warm up and stirred further 
for 5 h at RT. After the completion of reaction, mixture was quenched with sat.NH4Cl and 
extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (10% 
EtOAc/Hexane) to afford 38 (0.35 g, 52%) 
Physical appearance White viscous liquid 
Rf 0.5(EtOAc/Hexane 2:8) 
 
1H NMR (CDCl3) : 7.51-7.42 (2H, m); 7.41-7.31 (3H, m); 7.18 (2H, d, J = 8.2 Hz); 6.88 
(2H, d, J = 8.2 Hz); 6.23 (1H, d, J = 11.6 Hz); 5.58-5.44 (3H, m); 4.58 (2H, s); 3.90 (2H, s); 
3.82 (3H, s); 2.14-1.97 (2H, m); 1.75-1.14 (12H, m); 0.89 (3H, t, J = 7.3 Hz).  
Anal. calcd for C29H37NO3:  C, 77.82; H, 8.33; N, 3.13. Found: C, 78.10; H, 8.31; N, 3.14. 
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            1-(4-methoxybenzyl)-4-(dec-1-enyl)-3-methoxy-1H-pyrrol-2(5H)-one 
                                
N
O
O
O39
 
To the solution of 37 (0.1g, 0.16 mmol) was added LiHMDS (1 M in THF, 0.16 mL, 0.16 
mmol) at -78oC dropwise under nitrogen atmosphere. After stirring for 30 min, it was added a 
solution of n-nonanal (0.028g, 0.2 mmol) in THF. Then reaction was allowed to warm up and 
stirred further for 5 h at RT. After the completion of reaction, the mixture was quenched with 
sat.NH4Cl and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(10% EtOAc/Hexane) to afford 39 (0.040 g, 63%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) (mixture E/Z 7:3) : 7.14 (2H, d, J = 8.4 Hz, E+Z); 6.89 (2H, d, J = 8.4 
Hz, E+Z); 6.42 (1H, d, J = 16.2 Hz, E); 6.23 (1H, d, J = 11.5 Hz, Z); 5-76-5.50 (1H, m, E+Z); 
4.58 (2H, s, Z); 4.55 (2H, s, E); 4.08 (3H, s, Z); 4.07 (3H, s, E); 3.88 (2H, s, Z), 3.85 (3H, s, 
E+Z); 3.81 (2H, s, E); 2.17-1.99 (2H, m, E+Z); 1.44-1.16 (12H, m, E+Z); 0.89 (3H, t, J = 7.3 
Hz, E+Z). 
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H3N
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A mixture of L-valine 40 (5.0 g, 43 mmol), benzyl alcohol (18.5 g, 171 mmol) and p-toluene 
sulfonic acid monohydrate (8.9 g, 47 mmol) in toluene (71 mL) was heated at reflux for 5 h, 
with the removal of water via the aid of a Dean-Stark apparatus. The resulting reaction 
mixture was allowed to cool to room temperature, resulting in the formation of white crystals. 
The mixture was diluted with toluene (38 mL), cooled on an ice bath and the resulting 
precipitate collected via filtration, then washed with cold toluene (2  38 mL) and dried under 
reduced pressure to desired compound 41 (11.61 g, 91 %)  
Physical appearance White fluffy solid 
MP 155-156oC 
1H NMR : 8.22 (3H, brs); 7.74 (2H, d, J = 8.4 Hz); 7.32-7.25 (5H, m); 7.10 (2H, d, J = 8.4 
Hz); 5.13 (1H, d, J = 12.2 Hz, AB); 5.01 ( 1H, d, J = 12.2 Hz, AB); 3.90 (1H, m); 2.32 (3H, 
s); 2.20 (1H, m); 0.90 (3H, d, J = 6.7 Hz); 0.88 (3H, d, J = 6.7 Hz). 
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 2-[3-(1-Methoxycarbonyl-2-phenyl-ethyl)-ureido]-3-methyl-butyric acid benzyl ester 
                                                 
N
H
N
H
O
O
OO
O
42  
 
A mixture of L-valine benzyl ester p-toluenesulfonate 41 (2 g, 5.2 mmol) and 
diisopropylethylamine (1.49 g, 11 mmol) in dry DCM (20 mL) was slowly added to the 
stirred solution of triphosgene (0.57 g, 1.9 mmol) dropwise at RT. After a further 5 min 
stirring, a solution of L-phenylalanine methyl ester hydrochloride (1.13 g, 5.2 mmol) and 
DIEA (1.4 g, 11 mmol) was added in one portion. The reaction mixture was stirred for 10 
min at rt, evaporated to dryness, diluted with ethyl acetate, washed with 10% aqueous 
KHSO4, 5% aqueous NaHCO3, and brine, dried over Na2SO4, filtered and concentrated. The 
crude product was purified by flash column chromatography (40% EtOAc/Hexane) to afford 
42 (1.8 g, 85%) 
Physical appearance- White viscous liquid 
Rf   0.5 (EtOAc/Hexane 5:5) 
1H NMR (CDCl3) : 7.40-7.02 (10H, m); 5.30-4.98 (4H, m); 4.80 (1H, brs); 4.50 (1H, brs); 
3.70 (3H, s); 3.20-2.98 (2H, m); 2.09 (1H, m); 0.90 (3H, d, J = 7.2 Hz); 0.79 (3H, d, J = 7.2 
Hz). 
 120 
 
         2-[3-(1-Methoxycarbonyl-2-phenyl-ethyl)-ureido]-3-methyl-butyric acid 
                                             
N
H
N
H
O
O
OHO
O
43  
 
To the solution of 42 (1.5g, 3.6 mmol) in EtOAc (20 mL) was added a catalytic amount of 
10% Pd/C. Then reaction mixture was stirred for 1h at RT under hydrogen atmosphere. After 
the completion of reaction, the mixture was filtered through a celite bed and bed was washed 
with EtOAc three times. EtOAc was concentrated under vacuo. The crude product was 
purified by flash column chromatography (5% MeOH/DCM) to afford 43 (0.937 g, 80%) 
Physical appearance- white viscous liquid 
Rf 0.5 (MeOH/DCM 1:9) 
1H NMR (CDCl3) : 7.30-7.15 (3H, m); 7.11-7.01 (2H, m); 5.68-5.55 (2H, m); 4.80 (1H, m); 
4.36 (1H, m); 3.65 (3H, s); 3.13-3.04 (2H, m); 2.16 (1H, m); 0.95 (3H, d, J = 6.7 Hz); 0.87 
(3H, d, J = 6.7 Hz).  
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2-[3-(1-Methoxycarbonyl-2-phenyl-ethyl)-ureido]-3-methyl-butyricacid 
pentafluorophenyl ester 
 
                                                
N
H
N
H
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O
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A solution of acid 43 (0.5 g, 1.5 mmol), PFP (0.31 g, 1.7 mmol), DCC (0.35g, 1.7 mmol) in 
EtOAc (10 mL) was stirred at 0oC for 1h and then stirred for 3h at RT. The resultant mixture 
was filtered and the filtrate was concentrated under reduced pressure. The crude product was 
purified by flash column chromatography (25% EtOAc/Hexane) to afford 44 (0.5g, 66%) 
Physical appearance- white viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.30-7.18 (3H, m); 7.11-7.04 (2H, m); 5.38-5.26 (2H, m); 4.87-4.74 
(2H, m); 3.72 (3H, s); 3.09-3.02 (2H, m); 2.30 (1H, m); 1.05 (3H, d, J = 6.7 Hz); 0.96 (3H, d, 
J = 6.7 Hz). 
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2-[3-(1-Methoxycarbonyl-2-phenyl-ethyl)-ureido]-3-methyl-butyric acid 4-nitro-phenyl 
ester 
                                        
                                         
N
H
N
H
O
O
OO
O
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NO2
 
 
A solution of acid 43 (0.5 g, 1.5 mmol), p-nitrophenol (0.48 g, 3.4 mmol), DCC (0.48 g, 2.3 
mmol) in EtOAc (10mL) was stirred at 0oC for 1h and then stirred for 3h at RT. The resultant 
mixture was filtered and the filtrate was concentrated under reduced pressure. The crude 
product (0.612 g, 90%) was used for the next step without further purification. 
Physical appearance White solid 
Rf 0.5 (EtOAc/Hexane 2:8) 
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              Ethyl 4-(benzyloxy)-2,5-dihydro-5-oxo-1H-pyrrole-3-carboxylate                   
                                                            
N
H
O
OO
O
48  
To a stirred solution of 30 (5 g, 13 mmol) in ACN:Water (3:1) was added cerium ammonium 
nitrate (28 g, 52 mmol) at 0oC, then the solution was allowed to stir for 1h at room 
temperature. After the completion of reaction, the mixture was diluted with EtOAc and 
washed with water and brine solution. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(50% EtOAc/Hexane) to afford 48 (2.5 g, 73%) 
Physical appearance White solid 
Rf 0.3 (EtOAc/Hexane 5:5) 
1H NMR (CDCl3)  : 7.51-7.42 (2H, m); 7.41-7.30 (3H, m); 6.71 (1H, brs); 5.77 (2H, s); 4.29 
(2H, q, J = 7.0 Hz); 4.06 (2H, s); 1.34 (3H, t, J = 7.0 Hz).  
Anal. calcd for C14H15NO4: C, 64.36; H, 5.79; N, 5.36. Found: C, 64.60; H, 5.77; N, 5.35. 
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                                     (R)-2-amino-3-phenylpropan-1-ol 
                                                                      
H2N
OH
50  
To a cold solution of lithium borohydride (5.2 g, 24.19 mmol) in anhydrous THF (30mL) was 
added trimethylsilyl chloride (5.26 g , 48.39 mmol). The ice/water bath was removed and the 
mixture was allowed to stir at room temperature for 15 min. The mixture was recooled to 0 
°C, and L-phenylalanine (2.0 g, 12.09 mmol) was added. The ice/water bath was removed, 
and the reaction mixture was stirred overnight. The mixture was again cooled to 0°C, and 
methanol (45 mL) was added dropwise, followed by 2.5 M aqueous sodium hydroxide 
(25mL) This mixture was evaporated in vacuo, and the residue extracted with chloroform. 
The combined extracts were dried (Na2SO4), filtered, and evaporated in vacuo to give 50 (1.7 
g, 94.4%)  
Physical appearance White crystalline solid 
Rf   0.2 (MeOH/DCM 1:9) 
MP   90oC 
1H NMR (CDCl3) : 7.39-7.05 (5H, m); 3.64 (1H, dd, J = 3.7, 10.7 Hz); 3.38 (1H, dd, J = 
7.0, 10.7 Hz); 3.12 (1H, m); 2.79 (1H, dd, J = 5.3, 13.6 Hz); 2.53 (1H, dd, J = 13.6, 8.5 Hz). 
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        2-[3-(1-Benzyl-2-hydroxy-ethyl)-ureido]-3-methyl-butyric acid benzyl ester 
                                           
N
H
O
N
H O
OHO
51  
A mixture of L-valine benzyl ester p-toluenesulfonate 41 (1 g, 2.6 mmol) and 
diisopropylethylamine (0.749 g, 5.7 mmol) in dry DCM (20 mL) was slowly added to the 
stirred solution of triphosgene (0.289 g, 0.97 mmol) dropwise at RT. After a further 5 min 
stirring, a solution of L-phenylalaninol 50 (0.398g, 2.6 mmol) and DIEA (0.748 g, 5.7 mmol) 
was added in one portion. The reaction mixture was stirred for 10 min at RT, evaporated to 
dryness, diluted with ethyl acetate, washed with 10% aqueous KHSO4, 5% aqueous NaHCO3, 
and brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by 
flash column chromatography (60% EtOAc/Hexane) to afford 51 (0.750 g, 74%) 
Physical appearance- Yellowish viscous liquid 
Rf   0.4 (EtOAc/Hexane 6:4) 
1H NMR (CDCl3) : 7.42-7.15 (5H, m); 5.21-5.11 (2H, m); 4.50 (1H, t, J = 8.2 Hz); 4.39 
(1H, d, J = 4.6 Hz); 4.23-4.05 (2H, m); 3.93 (1H, m); 3.73 (1H, dd, J = 2.7, 11.0 Hz); 3.61 
(1H, dd, J = 6.4, 11.0 Hz); 2.97-2.69 (2H, m); 2.28-2.08 (1H, m); 0.92 (3H, d, J = 6.7 Hz); 
0.84 (3H, d, J = 6.7 Hz). 
 126 
2-{3-[1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-ureido}-3-methyl-butyric acid 
benzyl ester 
                                      
N
H
O
N
H O
OTBSO
52
 
To the solution of 51 (0.5 g, 1.3 mmol) in dry DCM (5 mL), imidazole (0.17 g, 2.6 mmol) 
was added portionwise at 0°C and the mixture was stirred for 10 min. TBSCl (0.39g, 2.6 
mmol) was added at 0°C and resulting reaction mixture was 4h at RT. The organic solvent 
was removed under reduced pressure .The residue was dissolved in EtOAc  and washed with 
water and brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (20% 
EtOAc/Hexane) to afford 52 (0.55 g, 85%) 
Physical appearance- Yellowish solid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.46-7.14 (5H, m); 5.22 (1H, d, J = 12.5 Hz, AB); 5.14 (1H, d, J = 12.5 
Hz, AB); 4.81 (2H, brs); 4.48 (1H, brs); 3.97 (1H, m); 3.56 (1H, dd, J = 4.3, 10.0 Hz); 3.50 
(1H, dd, J = 3.0, 10.0 Hz); 2.90 (1H, dd, J = 5.8, 13.1 Hz); 2.81 (1H, dd, J = 4.9, 13.1 Hz); 
2.15 (1H, m); 0.94 (9H, s); 0.93 ( 3H, d, J = 7.0 Hz); 0.84 (3H, d, J = 7.0 Hz); 0.06 (6H, s). 
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 2-{3-[1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-ureido}-3-methyl-butyric acid 
                                              
N
H
O
N
H O
OHTBSO
53
 
To the solution of 52 (0.5 g, 1.0 mmol) in EtOAc (10 mL) was added a catalytic amount of 
10% Pd/C. Then reaction mixture was stirred for 1h at RT under hydrogen atmosphere. After 
the completion of reaction, the mixture was filtered through a celite bed and bed was washed 
with EtOAc three times. EtOAc was concentrated under vacuo. The crude product was 
purified by flash column chromatography (5% MeOH/DCM) to afford 53 (0.38 g, 92%) 
Physical appearance White viscous liquid 
Rf 0.5 (MeOH/DCM 1:9) 
 
1H NMR (CDCl3) : 7.36-7.11 (5H, m); 5.63 (1H, brs); 5.25 (1H, brs)4.15 (1H, m); 3.95 
(1H, m); 3.52-3.45 (2H, m); 2.85-2.75 (2H, m); 2.12 (1H, m); 1.10-0.80 (15H, m); 0.04 (6H, 
s).  
 128 
2-{3-[1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-ureido}-3-methyl-butyric acid 
4-nitro-phenyl ester 
                                            
N
H
O
N
H O
OTBSO
54 NO2  
 
A solution of acid 53 (0.5 g, 1.2mmol), p-nitrophenol  (0.187 g, 1.3 mmol), DCC (0.268 g, 
1.3 mmol) in EtOAc (10mL) was stirred  at 0°C for 1h and then stirred for 3h at RT. The 
resultant mixture was filtered and the filtrate was concentrated under reduced pressure. The 
crude product was purified by flash column chromatography (15%EtOAc/Hexane) to afford 
54 (0.5 g, 77%) 
Physical appearance Yellowish viscous liquid  
Rf 0.4 (EtOAc/Hexane 1:9) 
 
1H NMR (CDCl3)  : 8.30 (2H, d, J = 9.2 Hz); 7.35-7.17 (7H, m); 4.81 (1H, brs); 4.62 (1H, 
brs); 4.13 (1H, m); 4.00 (1H, m); 3.67-3.47 (2H, m); 2.93-2.82 (2H, m); 2.29 (1H, m); 1.10 
(3H, d, J = 6.7 Hz); 1.04 (3H, d, J = 6.7 Hz); 0.95 (9H, s); 0.07 (6H, s). 
 129 
1-(2-{3-[1-Benzyl-2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-ureido}-3-methyl-butyryl)-4-
benzyloxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester 
                                          
N
H
O
N
H O
NTBSO
O
O
O
O
55  
 
A stirred solution of NaH (0.02 g, 0.4 mmol) in dry THF (2 mL) was added to a solution of 
amide 48 (0.1 g, 0.3 mmol) in THF (2 mL) at 0°C, The mixture was allowed to stir for 10 
min and then added with a solution of the activated ester 54 (0.2 g, 0.3 mmol) in THF (2 mL). 
Then reaction was allowed to stir for 30 min at 0°C. After the completion of reaction, the 
mixture was quenched with sat NH4Cl, extracted with EtOAc. The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by flash 
column chromatography (20% EtOAc/Hexane) to afford 55 (0.05g, 20%) 
Physical appearance White viscous oil. 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.51-7.14 (5H, m); 5.69 (1H, AB); 5.62 (1H, AB); 5.53 (1H, brs); 5.14 
(1H, brs), 4.92 (1H, m); 4.40-4.20 (4H, m); 3.98 (1H, m); 3.58 (1H, dd, J = 4.3, 10.1 Hz); 
3.51 (1H, dd, J = 3.4, 10.1 Hz); 2.93-2.78 (2H, m); 2.12 (1H, s); 1.34 (3H, t, J = 7.0 Hz); 1.07 
(3H, d, J = 7.0 Hz); 0.94 (9H, s); 0.84 (3H, d, J = 7.0 Hz); 0.07 (6H, s). 
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        Tert-butyl (S)-1-((pentafluorophenoxy)carbonyl)-2-methylpropylcarbamate            
                                                         
BocHN O
O
F
F
F
F
F
57  
N-Boc-L-Valine (2g, 9.2mmol), C6F5OH (1.86g, 10.12mmol) and DCC (2g, 10.12mmol) 
were added to EtOAc (30mL) at 0°C. The mixture was stirred at 0oC for 1 h, then at room 
temperature for 3 h. After filtration, the solvent was removed and the residue was purified by 
column chromatography on silica gel (6% EtOAc /Hexane) to give activated ester 57 (3.2g, 
91.42%)  
Physical appearance White solid 
Rf 0.6 (EtOAc/Hexane 1:9)  
1H NMR (CDCl3)  : 5.04 (1H, m); 4.60 (1H, m); 2.35 (1H, m); 1.49 (9H, s); 1.11 (3H, d, J = 
7.0 Hz), 1.05 (3H, d, J = 7.0 Hz).  
Anal. calcd for C16H18F5NO4: C, 50.13; H, 4.73; N, 3.65. Found: C, 49.94; H, 4.72; N, 3.66. 
 131 
4-Benzyloxy-1-(2-tert-butoxycarbonylamino-3-methyl-butyryl)-5-oxo-2,5-dihydro-1H-
pyrrole-3-carboxylic acid ethyl ester 
                                               
BocHN
N
O O
O
O
O
58  
To a stirred solution of 48 (1.0g, 3.8 mmol) in anhydrous THF (30mL) was added n-BuLi 
(1.6M in hexane, 2.6mL, 4.2mmol) at –78 °C over 10 min. Active ester 57 (1.6g, 4.2mmol) in 
THF (2mL) was then added, and the mixture was stirred for 30 min at the same temperature. 
The reaction was quenched with sat. NH4Cl and extracted with EtOAc (3 ×15mL). The 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product 
was purified by flash column chromatography (12% EtOAc/Hexane) to afford 58 (6 g, 86%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3)  : 7.50-7.31 (5H, m); 5.67 (2H, s); 5.41 (1H, m); 4.35 (1H, AB); 4.31 (2H, 
q, J = 7.0 Hz); 4.30 (1H, AB); 4.14 (2H, q, J = 7.0 Hz, 2nd rotamer); 2.15 (1H, m); 1.46 (9H, 
s); 1.34 (3H, t, J = 7.0 Hz); 1.28 (3H, t, J = 7.0 Hz, 2nd rotamer); 1.11 (3H, d, J = 7.0 Hz); 
0.84 (3H, d, J = 7.0 Hz, 2nd rotamer).  
Anal. calcd for C24H32N2O7: C, 62.59; H. 7.00; N, 6.08. Found: C, 62.80; H. 7.02; N, 6.09. 
 
 
 132 
{1-[(3-Benzyloxy-4-hydroxymethyl-2-oxo-2,5-dihydro-pyrrol-1-yl)-hydroxy-methyl]-2-
methyl-propyl}-carbamic acid tert-butyl ester 
                                              
BocHN N
OH O
O
HO
59
 
To the solution of 58 (1 g, 2.1 mmol)  in dry DCM (20mL) was added diisobutylaluminium 
hydride (1.0 M in DCM, 5.4mL, 5.4mmol) at -78oC and stirred for 2.5h at the same 
temperature. After completion of reaction, the mixture was quenched with sat. Rochelle salt 
and EtOAc was added, stirring for 10 min. The aqueous phase was extracted three times with 
EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The 
crude product was purified by flash column chromatography (40% EtOAc/Hexane) to afford 
59 (0.27 g, 30%) 
Physical appearance Yellowish solid. 
Rf 0.3 (EtOAc/Hexane 4:6) 
1H NMR (CDCl3) : 756-7.30 (5H, m); 5.47 (1H, d, J = 9.4 Hz); 5.29 (1H, d, J = 11.9 Hz, 
AB); 5.16 (1H, d, J = 11.9 Hz, AB); 4.63 (1H, d, J = 11.0 Hz); 4.35-4.02 (4H, m); 3.80 (1H, 
m); 2.23 (1H, m); 1.44 (9H, s); 0.99 (3H, d, J = 7.3 Hz); 0.94 (3H, d, J = 7.3 Hz). 
 133 
1-(2-Amino-1-hydroxy-3-methyl-butyl)-4-benzyloxy-5-oxo-2,5-dihydro-1H-pyrrole-3-
carbaldehyde 
                                          
H2N
N
OH O
O
O
60
 
    To a stirred solution of oxalyl chloride (0.37 mL, 4. 3 mmol) in dry DCM (3 mL), was 
added DMSO (0.4 mL, 5.7 mmol) in dry DCM (3 mL) dropwise at -78 °C under N2 
atmosphere. Stirring was continued for 15 min, then 59 (0.6 g, 1.43 mmol) in dry DCM (10 
mL) was added dropwise. After complete addition, the reaction mixture was stirred at -78 °C 
for 1 h, then NEt3 (1.98 mL, 14.33mmol) was added dropwise. The reaction mixture was 
gradually warmed to 0°C and stirred at this temperature till complete conversion was 
observed. The mixture was diluted with diethyl ether and poured in cold sat. NaHCO3. The 
organic layer was separated; and the aqueous layer was extracted with diethyl ether (3×150 
mL). The combined organic extracts were washed with brine, dried over anhydrous Na2SO4 
and concentrated. The crude product was purified by flash column chromatography (20% 
EtOAc/Hexane) to afford 60 (0.3 g, 60%) 
Physical appearance Yellowish Solid. 
Rf 0.5 (EtOAc/Hexane 5:5) 
1H NMR (CDCl3) : 10.11 (1H, s); 7.49-7.36 (5H, m); 6.18 (1H, d, J = 3.9 Hz); 6.12 (1H, 
brs); 5.72 (2H, s); 4.19-4.02 (2H, m); 3.49 (1H, dd, J = 3.9, 6.7 Hz); 1.90 (1H, m); 1.01 (3H, 
d, J = 6.7 Hz); 0.99 (3H, d, J = 6.7 Hz). 
 
 
 
 134 
 
                                      n-Nonyltriphenylphosphonium bromide 
 
                                                         
PPh3+Br-
61  
A solution of 1-bromononane (1 g, 4.8 mmol) and triphenylphosphine (1.5 g, 5.7 mmol) in 20 
mL of toluene was refluxed overnight. The reaction mixture was then cooled to room 
temperature and poured into diethyl ether. The resulting oil was washed three times with 
ether, dissolved in CH2Cl2 and then concentrated in vacuo. The oil was left standing in 
diethyl ether at 0C overnight and then concentrated in vacuo to give the desired 
phosphonium bromide 61 (1.8 g, 94%)  
Physical appearance Yellowish sticky solid 
Rf 0.5 (MeOH/DCM 1:9) 
1H NMR (CDCl3) : 7.98-7.60 (15H, m); 3.90-3.62 (2H, m); 190-1.10 (14H, m); 0.89 (3H, 
m). 
 135 
  1-(2-Amino-1-hydroxy-3-methyl-butyl)-3-benzyloxy-4-dec-1-enyl-1,5-dihydro-pyrrol-
2-one 
                                                 
H2N
N
O
O
HO
62/63
 
To an ice cold solution of (1-Nonyl)triphenylphosphonium bromide 61 (0.623 g, 1.3 mmol) 
in 10mL of dry THF under nitrogen was added dropwisely (0.790 mL,1.6 M,1.2 mmol) of  n-
BuLi in Hexane  and then allowed stir for 45 min at same temperature. Then orange solution 
was cooled to -78°C and added aldehyde 60 (0.2g, 0.63mmol) in dry THF was added 
dropwise. After addition was completed, the reaction was stirred for 1 h at -78°C,warmed to 
0°C and quenched with added Sat. NH4Cl. . The aqueous phase was extracted three times 
with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. 
The crude product was purified by flash column chromatography (40% EtOAc/Hexane) to 
afford 62/63 (0.2 g, 73.8%) 
Physical appearance White viscous liquid 
Rf 0.6 (EtOAc/Hexane 5:5) 
1H NMR (CDCl3) : 7.44-7.28 (5H, m); 6.27-6.15 (2H, m); 5.94 (1H, brs); 5.63 (1H, m); 
5.45-5.30 (2H, m, AB); 4.16 (1H, d, J = 16.8 Hz, AB); 4.04 (1H, d, J = 16.8 Hz, AB); 3.51 
(1H, m); 2.18-2.06 (2H, m); 1.78-1.64 (4H, m); 1.50-1.15 (12H, m); 1.00 (3H, d, J = 6.7 Hz); 
0.97 (3H, d, J = 6.7 Hz).  
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 2-{[5-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrol-1-yl)-4-isopropyl-2-oxo-
oxazolidine-3-carbonyl]-amino}-3-phenyl-propionic acid benzyl ester 
                                              
N N
OBn
O
N
H
O
BnO
O
Ph
O
O
E/Z
65/66  
A mixture of L-phenylalanine benzyl ester 64 (0.059 g, 0.2 mmol) and diisopropylethylamide 
(0.06 g, 0.5 mmol) in dry DCM (2mL) was slowly added to the stirred solution of triphosgene 
(0.025 g, 0.086 mmol) dropwise at RT. After a further 15 min stirring, a solution of 62/63 
(0.1 g, 0.2 mmol) and DIEA (0.06 g, 0.5 mmol) in dry DCM (2 mL) was added in one 
portion. The reaction mixture was stirred for 3 days at RT, evaporated to dryness, diluted 
with ethyl acetate, washed with 10% aqueous KHSO4, 5% aqueous NaHCO3, and brine, dried 
over Na2SO4, filtered and concentrated. The crude product 65/66 (0.05g, 30%) was used for 
the next step without further purification. 
Physical appearance- White viscous liquid 
Rf  0.5  (EtOAc/Hexane 5:5) 
 137 
2-{[5-(4-Decyl-3-hydroxy-2-oxo-2,5-dihydro-pyrrol-1-yl)-4-isopropyl-2-oxo-oxazolidine-
3-carbonyl]-amino}-3-phenyl-propionic acid 
                                         
N N
OH
O
N
H
O
HO
O
Ph
O
O
67  
To the solution of 65/66 (0.04 g, 0.05 mmol) in EtOAc (10mL) was added a catalytic amount 
of 10%Pd/C. Then reaction mixture was stirred for 2h at RT under hydrogen atmosphere. 
After the completion of reaction, the mixture was filtered through a celite bed and the bed 
was washed with EtOAc three times. EtOAc was concentrated under vacuo. The crude 
product was purified by flash column chromatography (05%MeOH/DCM) to afford 67 
(0.015 g, 50%) 
Physical appearance White viscous liquid 
Rf 0.5 (MeOH/DCM 1:9) 
 
1H NMR (CDCl3) : 8.19 (1H, d, J = 7.9 Hz); 7.36-7.21 (5H, m); 6.03 (1H, d, J = 2.4 Hz); 
4.77 (1H, m); 4.23 (1H, dd, J = 2.4, 4.0 Hz); 3.74-3.59 (2H, m, AB); 3.32 (1H, dd, J = 15.1, 
14.1 Hz); 3.11 (1H, dd, J = 14.1, 8.5 Hz); 2.49-2.30 (3H, m); 1.60-1.45 (2H, m); 1.40-1.20 
(14H, m); 0.94 (3H, d, J = 7.3 Hz); 0.93 (3H, d, J = 7.3 Hz); 0.88 (3H, t, J = 7.2 Hz). 
13C NMR (DMSO) : 172.1, 167.5, 153.8, 149.4, 141.0, 137.6, 129.5, 127.9, 126.1, 125.8, 
77.2, 60.7, 55.1, 44.3,  37.0, 31.3, 29.0, 28.96, 28.8, 28.7, 28.3, 27.4, 24.8, 22.1, 16.9, 14.5, 
13.9. 
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 [1-(3-Benzyloxy-4-formyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-propyl]-
carbamic acid tert-butyl ester                                            
                                                   
BocHN
O
N
O
O
O
68  
To the stirred solution of compound 59 (0.22 g, 0.5 mmol) in DCM (5 mL) was added PCC 
(1.12 g, 5.23 mmol) at 0oC, then the solution was allowed to stir for 48 h at RT. After 
completion of reaction, the mixture was filtered through a celite bed and washed with DCM. 
The DCM was concentrated under vacuo. The crude product was purified by flash column 
chromatography (20% EtOAc/Hexane) to afford 68 (0.087 g, 40%) 
 Physical appearance- White viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 10.14 (1H, s); 7.51-7.31 (5H, m); 5.72-5.59 (2H, m, AB); 5.41 (1H, dd, 
J = 3.4, 9.5 Hz); 5.18 (1H, d, J = 9.5 Hz); 4.40 (1H, d, J = 18.8 Hz, AB); 4.24 (1H, d, 18.8 
Hz, AB); 2.14 (1H, m); 1.44 (9H, s); 1.09 (3H, d, J = 7.1 Hz); 0.84 (3H, d, J = 7.1 Hz). 
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[1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-propyl]-
carbamic acid tert-butyl ester 
                                                  
BocHN
O
N
O
O
69  
To an ice cold solution of (1-nonyl)triphenylphosphonium bromide 61 (0.067 g, 0.144 mmol) 
in 3 mL of dry THF under nitrogen was added dropwise ( 0.18 mL,1.6 M, 0.18 mmol)  n-
BuLi in Hexane  and then the mixture was allowed stir for 45 min at the same temperature. 
Then orange solution was cooled to -78°C and aldehyde 68 (0.030 g, 0.072 mmol) in dry 
THF was added dropwise. After addition was completed, the reaction was stirred for 1 h at -
78°C, warmed to 0°C and quenched with added Sat. NH4Cl. The aqueous phase was 
extracted three times with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. To give crude 69 (0.013 g, 36 %) which was used for the next step 
without further purification. 
Physical appearance- Colorless liquid 
Rf 0.4 (EtOAc/Hexane 1:9) 
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1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-propyl-
ammonium; trifluoro-acetate 
                                       
+H3N
O
N
O
O
F3C O
O
70  
To a stirred solution of compound 69 (0.02 g, 0.037 mmol) in dry DCM (2 mL) was added 
TFA (0.05 mL) at 0oC. The reaction mixture was allowed to stir at room temperature for 4h. 
After completion of the reaction, the mixture was concentrated under vacuo. The residue was 
triturated with diethyl ether and dried under vacuum, to afford 70 (0.015g, 73%). The crude 
product was used for the next step without further purification. 
Physical appearance- White sticky solid. 
Rf 0.2(MeOH/DCM 1:9) 
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2-{3-[1-(3-Benzyloxy-4-dec-1-enyl-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-
propyl]-ureido}-3-phenyl-propionic acid benzyl ester 
                                            
N
H
N OBn
O
N
H
O
BnO
O
Ph
O
71  
A mixture of L-phenylalanine benzyl ester 64 (0.016 g, 0.036 mmol) and 
diisopropylethylamide (0.010 g, 0.081 mmol) in dry DCM (2 mL) was slowly added to the 
stirred solution of triphosgene (0.004 g, 0.013 mmol) dropwise at RT. After a further 15 min 
stirring, a solution of 70 (0.020 g, 0.036 mmol) and DIEA (0.010 g, 0.081 mmol) in dry 
DCM ( 2 mL) was added in one portion. The reaction mixture was stirred for 24h at RT, 
evaporated to dryness, diluted with ethyl acetate, washed with 10% aqueous KHSO4, 5% 
aqueous NaHCO3, and brine, dried over Na2SO4, filtered and concentrated. The crude product 
was used for the next step without further purification. 
Physical appearance-White viscous liquid. 
Rf 0.4 (EtOAc/Hexane 3:7) 
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2-{3-[1-(4-Decyl-3-hydroxy-2-oxo-2,5-dihydro-pyrrole-1-carbonyl)-2-methyl-propyl]-
ureido}-3-phenyl-propionic acid 
                                               
N
H
N OH
O
N
H
O
HO
O
Ph
O
1
 
To the solution of 71 (0.02 g, 0.025 mmol) in EtOAc (5 mL) was added a catalytic amount of 
10% Pd/C. Then reaction mixture was stirred for 2h at RT under hydrogen atmosphere. After 
the completion of reaction, the mixture was filtered through a celite bed and the bed was 
washed with EtOAc three times. EtOAc was concentrated under vacuo. The crude product 
was purified by flash column chromatography (0.5% MeOH/DCM) to afford 1 (0.01 g, 80 %) 
Physical appearance- Clear oil. 
Rf 0.4 (MeOH/DCM 1:9) 
1H NMR (DMSO) : 9.46 (1H, s); 7.28 (2H, dd, J = 7.6, 7.3 Hz); 7.19 (2H, d, J = 7.3 Hz); 
7.21 (1H, dd, J = 7.6, 7.7 Hz) ;  6.47 (1H, d, J = 9.3 Hz) ; 6.35 (1H, d, J = 8.0 Hz) ; 5.36 (1H, 
dd, J = 9.3, 3.7 Hz) ; 4.29 (1H, m); 4.09 (1H, d, J = 18.6 Hz); 4.00(1H, d, J=18.6 Hz) ; 
2.99(1H, dd, J = 14.3, 5.2 Hz); 2.84 (1H, dd, J = 14.3, 5.3 Hz); 2.00 (1H, m); 2.30 (2H, m); 
1.22-1.44 (16H, m);  0.91(1H, d, J = 7.2 Hz); 0.75 (1H, d J = 7.2 Hz); 0.87 (1H, t, J = 6.7 Hz) 
13C NMR (DMSO) :174.2, 172.5, 166.5, 157.8, 141.7, 137.9, 129.6, 129.2, 128.5,126.6, 
56.9, 54.3, 46.5, 37.9,31.7, 30.2, 29.2, 29.6, 29.6, 29.6, 29.6, 27.2, 25.2, 22.3, 19.9, 16.6, 14.3
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                                Ethyl 2-(4-methoxybenzylamino)acetate 
 
                                                     
N
H
O
O
O
86
 
 Ethyl bromoacetate (1.0 g, 7.2 mmol) in THF (20 mL) was added dropwise to a cooled 
solution of p-methoxybenzylamine(1.27 g,7.6 mmol) . After stirring 2.5 h, reaction mixture 
was filtered and the filtrate was concentrated under vacuo. The crude product was purified by 
flash column chromatography (80% Ether/Hexane) to afford 86 (1.4g, 87%) 
Physical appearance White viscous liquid 
Rf  0.5 (Ether/Hexane 9:1) 
1H NMR (CDCl3) : 7.26 (2H, d, J = 8.2 Hz); 6.88 (2H, d, J = 8.2 Hz); 4.20 (2H, q, J = 7.3 
Hz); 3.81 (3H, s); 3.76 (2H, s); 3.41 (2H, s); 1.29 (3H, t, J = 7.3 Hz). 
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                           Ethyl 2-(N-(4-methoxybenzyl)dodecanamido)acetate 
                                                         
N
O
O
OO
87
 
Dodecanoyl chloride (1.1g, 8.8 mmol) was added dropwise to the solution of compound 86 
(1.0 g, 4.4 mmol) and TEA (0.9 g, 8.9mmol) in CHCl3 at 0C over 10 min. After completion 
of reaction the mixture was diluted with CHCl3 and washed with water and brine solution. 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated . The crude 
product was purified by flash column chromatography (60% Ether/Hexane) to afford 87 
(1.5g, 83%) 
Physical appearance White viscous liquid 
Rf 0.5(EtOAc/Hexane 5:5) 
1H NMR (CDCl3) : 7.13 (2H, d, J = 8.8 Hz); 6.90 (2H, d, J = 8.8 Hz); 4.58 (2H, s); 4.18 
(2H, q, J = 7.3 Hz); 4.02 (2H, s); 3.82 (3H, s); 2.46 (2H, t, J = 7.3 Hz); 1.75-1.58 (2H, m); 
1.41-1.117 (16H, m); 0.89 (3H, t, J = 7.3 Hz). 
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     N-Ethoxycarbonylmethyl-N-(4-methoxy-benzyl)-malonamic acid benzyl ester 
                                                
N
O
O
OO
O OBn
84  
To the solution of 87 (2.4 g,  10.75 mmol) in DCM was added benzyl hydrogen malonate 
(4.1g, 21.51 mmol) at 0C, followed by a solution of DCC (3.32 g, 16.13 mmol) and DMAP 
(0.065 g, 0.5 mmol) in DCM. The solution was allowed to stir at RT for 12h. After the 
completion of reaction, the mixture was filtered and the filtrate was washed with water and 
brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (10% 
EtOAc/Hexane) to afford 88 (3.0g, 83%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3 : 7.42-7.28 (5H, m); 7.21-7.03 (2H, m); 6.93-6.76 (2H, m); 5.18 (2H, s); 
4.55 (2H, s); 4.16 (2H, q, J = 7.3 Hz); 4.05 (2H, s); 3.80 (3H, s); 3.63 (2H, s); 1.23 (3H, t, J = 
7.3 Hz). 
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        Benzyl 1-(4-methoxybenzyl)-3-decyl-2,4-dioxopyrrolidine-3-carboxylate 
                                                            
N
PMB
O
O
O
OBn
89  
Tetrabutylammonium fluoride (9.5 mL,9.5 mmol) was added to a solution of  diester 88 (1.9 
g, 4.7 mmol) and diethyl ether; the mixture was stirred for under nitrogen  at room 
temperature for 2h , and the colourless solid was removed by filtration and washed with 
diethyl ether. The solid was suspended in THF at room temperature, and decyl iodide (2.5 g, 
9.5 mmol) was added. The mixture was stirred for twenty four hours, and evaporated to 
dryness. The crude was purified by column chromatography to afford  89 (0.69 g, 30%) 
Physical appearance White viscous liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3 : 7.46-7.28 (3H, m); 7.28-7.15 (2H, m); 7.14-6.99 (2H, m); 6.81-6.63 (2H, 
m); 5.15 (2H, s); 4.79 (1H, d, J = 14.6 Hz, AB); 4.44 (1H, d, J = 14.6 Hz, AB); 3.82 (1H, d, J 
= 17.8 Hz, AB); 3.77 (3H, s); 3.57 (1H, d, J = 17.8 Hz, AB); 2.18 (2H, m); 1.48-1-1.12 (16H, 
m); 0.88 (3H, t, J = 7.2 Hz). 
 147 
 
                      Benzyl 3-decyl-2,4-dioxopyrrolidine-3-carboxylate
 
                                                              
N
H
O
O
O
OBn
90  
To the stirred solution of 89 (0.1 g, 0.2 mmol) in ACN:Water (3:1) was added cerium 
ammonium nitrate (0.3g, 0.6mmol) at 0oC. The solution was then allowed to stir for 1h at 
room temperature. After the completion of reaction, the mixture was diluted with EtOAc and 
washed with water and brine solution. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated. The crude product was purified by flash column chromatography 
(30% EtOAc/Hexane) to afford 90 (0.05 g, 66%) 
Physical appearance Colorless liquid  
Rf 0.5 (EtOAc/Hexane 5:5) 
1H NMR (CDCl3) : 7.43-7.17 (5H, m); 6.95 (1H, brs); 5.16 (2H, s); 4.05 (2H, d, J = 18.1 
Hz, AB); 3.81 (2H, d, J = 18.1 Hz, AB); 2.16 (2H, m); 1.46-0.96 (16H, m); 0.88 (3H, t, J = 
7.3 Hz). 
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                                                              CHAPTER 4 
                               Synthesis of 2,3-pyrrolidinedione derivatives 
 
4.1 Introduction 
              
Leopolic Acid possesses a 2,3-pyrrolidinedione core (2). This is a very attractive 
skeleton as natural compounds with the isomeric 2,4-pyrrolidinedione ring (1, tetramic acids) 
show remarkable activities, ranging from antibacterial and antiviral to antifungal as well as 
anticancer, as discussed in Chapter 3.  
On the contrary, compounds with a 2,3-pyrrolidinedione skeleton have been much less 
investigated. To the best of our knowledge, only leopolic acid1 and a few synthetic 
compounds2-4 have been reported in the literature so far. Therefore, this skeleton can be 
considered a very attractive target for biological evaluation, offering the possibility of 
preparing products with several points of diversity, similarly to what occurred for tetramic 
acid. Thus, using leopolic acid as a starting point, we planned to develop a chemical routes to 
the substituted 2,3-pyrrolidinedione core, with the aim of preparing derivatives with a wide 
range of diversity. In the perspective of a potential evaluation of their antifungal and 
antimicrobial activity, a number of analogues with various substituents on the 2,3 
pyrrolidinedione core were synthesized.  
 
4.2 Synthesis 
We envisaged that the most straightforward route to the synthesis of the 2,3-pyrrolidinedione 
system could be the Michael addition of a suitably protected amine to ethyl acrylate, followed 
by a Dieckmann cyclization with diethyl oxalate.5 We opted for the p-methoxybenzyl (PMB) 
protecting group, which could be easily removed by cerium ammonium nitrate (CAN) or 2,3-
dichloro-5,6-dicyanobenzoquinone (DDQ). 
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Thus, ethyl acrylate 3 was reacted with p-methoxybenzylamine to obtain compound 4, which 
was then treated with diethyl oxalate to give 2,3-pyrrolidinedione 5. (Scheme 4.1). NMR 
observations showed that the compound exists as an enol tautomer (see SI). Indeed, it has 
been reported6-8 that apparently all 4-monosubstituted 2,3-dioxopyrrolidines are highly 
enolized, regardless of the nature of the substituent in position 4.  
With compound 5 in hands, we planned to prepare a series of analogues to obtain a range of 
diversity around the heterocyclic core. Initially, it was decided to compare different 
functionalities at position 4. The enolic OH was first protected with a tertbutylsilyl (TBS) 
group, by treatment of 5 with TBSCl, to obtain compound 6.  
Scheme 4.1. Synthesis of compounds 5-9. 
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(a) pmethoxybenzylamine, EtOH, rt, 12h, 98%; (b) diethyloxalate, NaOEt, EtOH, reflux, 3h, 83%; (c) TBSCl, 
imidazole, DCM, rt, 6h, 86%; (d) DIBAL-H, DCM, -78°C to rt, 1h, 72%; (e) PPH3, CBr4, DCM, rt, 12h, 87%; 
(f) PPh3, toluene, reflux, 6h, 61%; (g) n-nonanal, LiHMDS, THF, -78°C to rt, 5h, 88%; (h) H2/Pd/C, EtOAc, rt, 
1h, 89%
a
d f, g, h
b c
8
 
Reduction of 6 with diisobutylaluminium hydride (DIBALH) successfully gave alcohol 7 in 
72% yield. Inspired by Leopolic acid we planned the synthesis of a 4-alkyl substituted 
derivative. Thus, alcohol 7 was converted into the corresponding bromide by Appel reaction 
with PPh3 and CBr4. The bromide was reacted with PPh3 to give a bromonium salt which was 
then subjected to Wittig reaction with a nine-carbons aldehyde. Reduction of the double bond 
by catalytic hydrogenation gave compound 9 in 89% yield. 
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Unfortunately, attempts to remove the PMB group from compounds 6-9 (CAN in ACN 
/water or DDQ, CH2Cl2) resulted into unstable compounds which decomposed during 
purification. 
Assuming that this instability could be due to the enol protecting group, we decided to use a 
benzyl group as an alternative. Thus, compound 5 was treated with benzyl bromide to obtain 
compound 10 (Scheme 4.2). To compare compounds with the benzyl group to analogues with 
the TBS group on the enolic OH, we repeated on compound 10 (Scheme 2) the same 
sequence reported above for compound 6 (see Scheme 1). Reduction with DIBALH, followed 
by Appel bromination and Wittig reaction, allowed the introduction in position 4 of the 
aliphatic chain (compound 14).  
Deprotection of PMB group from compound 10 was successful and gave 14. Having the 
compound with a free NH in hands, we explored the effect of a polar group linked to 
nitrogen, to compare with compound 10, carrying a lipophilic PMB group. Thus, 14 was 
acylated with activated N-protected valine, already present in Leopolic acid to obtain 15. 
Removal of the Boc protecting group afforded 16, containing the free aminoacidic residue. 
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Scheme 4.2. Synthesis of compounds 10-16. 
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(a) DIBAL-H, DCM, -78°C to rt, 1h, 56%; (b) PPh3, CBr4, DCM, rt, 3h, 52%; (c) PPh3, 
toluenene, reflux, 6h, 75%; (d) n-nonanal, LiHMDS, THF, -78°C, 5h, 52%; (e)  BnBr, K2CO3, 
DMF, rt, 1h, 50%; (f) CAN, ACN: water, rt, 1h, 73%; (g) 
2-tert-butoxycarbonylamino-3-methyl-butyric acid pentafluorophenyl ester, BuLi, THF, -78°C 
to rt, 0.5h, 86%; (h) TFA, DCM, 0°C, 0.5h, 90%.
a
c, d
g h
7
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4.3 Experimental section 
For general experimental methods, see Chapter 3 
The preparation of compounds 3-15 is described in Chapter 3 
 
 (S)-1-(3-(benzyloxy)-4-(ethoxycarbonyl)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-3-methyl-1-
oxobutan-2-aminium 2,2,2-trifluoroacetate (16) 
 
                                              
H3N
N
O O
OBn
O
O
F3C O
O
 
 
To a stirred solution of compound 15 (0.10 g, 0.21 mmol) in dry DCM (3 mL) was added 
TFA (1 mL) at 0oC. The reaction mixture was allowed to stir at room temperature for 1h. 
After completion of the reaction, the mixture was concentrated under vacuo. The residue was 
triturated with diethyl ether and dried under vacuum, to afford 16 (0.09 g, 90%) as a white 
solid. 1H NMR (CDCl3)  7.46-7.26 (5H, m); 5.64-5.57 (2H, m); 5.07 (1H, m); 4.48 (1H, d, J 
= 19.8 Hz, AB); 4.28 (1H, d, J = 19.8 Hz, AB); 4.27 (2H, q, J = 7.3 Hz); 2.33 (1H, m); 1.32 
(3H, t, J = 7.3 Hz); 1.24 (3H, d, J = 7.0 Hz); 1.01 (3H, d, J = 7.0 Hz). Anal. calcd for 
C21H25F3N2O7: C, 53.16; H, 5.31; N, 5.90. Found: C, 53.33; H, 5.30; N, 5.91. 
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4-Methoxy-1-(4-methoxybenzyl)-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl 
ester (19) 
 
                                                      
N
PMB
O
O
O
O
 
      
To a stirred solution of 5 (0.50 g, 1.71 mmol) in dry DMF(10 mL) was added anhydrous 
K2CO3 (0.71 g, 5.14 mmol) at 0°C. The solution was stirred for 15 min, then MeI (0.29 g, 
2.05 mmol) was added. The reaction mixture was allowed to warm up and stirred for further 
1h. After completion of reaction, the mixture was diluted with EtOAc and washed with cold 
brine solution. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (30% 
EtOAc/Hexane) to afford 19 (0.32 g, 61%) as a white sticky solid. Rf 0.4 (EtOAc/Hexane 
1:1). 1H NMR (CDCl3) : 7.20 (2H, d, J = 8.5 Hz); 6.88 (2H, d, J = 8.5 Hz); 4.58 (2H, s); 
4.34 (3H, s); 4.22 (2H, q, J = 7.0 Hz); 3.86 (2H, s); 3.81 (3H, s); 1.29 (3H, t, J = 7.0 Hz). 
Anal. calcd for C16H19NO5: C, 62.94; H, 6.27; N, 4.59. Found: C, 62.70; H, 6.26; N, 4.60. 
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       4-Methoxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid ethyl ester (20) 
                                                         NH
O
O
O
O
 
To a stirred solution of 19 (0.25 g, 0.81 mmol) in ACN:Water (3:1) (8 mL) was added cerium 
ammonium nitrate (1.79 g, 3.27 mmol) at 0 °C. The mixture was stirred for 1h at room 
temperature, then it was diluted with EtOAc and washed with water and brine solution. The 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude product 
was purified by flash column chromatography (50% EtOAc/Hexane) to afford 20 (0.18 g, 
71%) as a colorless viscous oil. Rf  0.5 (EtOAc/Hexane 6:4). 1H NMR (CDCl3) : 4.37-4.23 
(6H, m); 4.07 (2H, s); 1.34 (3H, t, J = 7.0 Hz). Anal. calcd for C8H11NO4: C, 51.89; H, 5.99; 
N, 7.56. Found: C, 52.06; H, 6.01; N, 7.59. 
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 1-(2-tert-butoxycarbonylamino-3-methylbutyryl)-4-methoxy-5-oxo-2,5-dihydro-1H-
pyrrole-3-carboxylic acid ethyl ester (17) 
                                                       
BocHN
N
O O
O
O
O
 
  
To a stirred solution of 20 (0.12 g, 0.64 mmol) in anhydrous THF (2mL) was added n-BuLi 
(1.6 M in hexane, 0.40 mL, 0.64 mmol) at –78°C over 10 min. The active ester 18 (0.27 g, 
0.71 mmol) in THF (2 mL) was then added, and the mixture was stirred for 30 min at the 
same temperature. The reaction was quenched with sat. NH4Cl and extracted with EtOAc. 
The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The crude 
product was purified by flash column chromatography (16% EtOAc/Hexane) to afford 17 
(0.19 g, 80%) as a colorless viscous oil. Rf 0.5 (EtOAc/Hexane 2:8). 1H NMR (CDCl3)   
(mixture of rotamers): 5.39 (1H, d, J = 3.6 Hz); 5.36 (1H, d, J = 3.6 Hz, 2nd rotamer); 4.44 
(1H, d, J = 19.2 Hz, AB); 4.30 (2H, q, J = 7.0 Hz); 4.29 (1H, d, J = 19.2 Hz, AB); 4.27 (3H, 
s); 4.13 (2H, q, J = 7.0 Hz, 2nd rotamer); 1.45 (9H, s); 1.34 (3H, t, J = 7.0 Hz); 1.27 (3H, t, J = 
7.0 Hz, 2nd rotamer); 1.09 (3H, d, J = 6.7 Hz); 0.85 (3H, d, J = 6.7 Hz). Anal. calcd for 
C18H28N2O7: C, 56.24; H, 7.34; N, 7.29. Found: C, 56.03; H, 7.36; N, 7.28. 
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                                                           CHAPTER 5 
 
  Antimicrobial and antifungal activity evaluation of 2,3-pyrrolidinedione derivatives  
 
The prepared compounds containing the 2,3-pyrrolidinedione core (see Chapter 4)  were 
investigated for their antimicrobial and antifungal activity on S. mutans, C. cladosporioides 
and C. albicans. From the analysis of the results obtained preliminary structure-activity 
relationships (SAR) have emerged. 
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Table 1. Compounds tested 
Compound N° MW Solubility 
N
O
OH
O
O
O
 
5 291.30 
DCM 
EtOAc 
N
O
OTBS
O
O
O
 
6 405.56 
DCM 
EtOAc 
N
O
OTBS
HO
O
 
7 363.52 
DCM 
EtOAc 
N
O
OTBS
O
 
9 473.33 
DCM 
EtOAc 
N
O
OBn
O
O
O
 
10 381.16 
DCM 
EtOAc 
N
O
OBn
HO
O
 
11 339.39 
DCM 
EtOAc 
N
O
OBn
O
 
13 471.3 
DCM 
EtOAc 
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N
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14   
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O
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15 460.52 
DCM 
EtOAc 
N
O
O
O
O
O
NH3 O
O
F
FF
 
16 474.43 
DCM 
EtOAc 
N
O
O
O
O
O
NHBoc
 
17 384.42 
DCM 
EtOAc 
 
CHX1   
2chlorhexidine (positive control). 
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5.1 Antimicrobial activity against Streptococcus mutans and Candida albicans  
 
The results of antibacterial activity are shown in Figure 1 and Table 2. 
Compound 5, containing a free enolic OH, showed a mean OD of 0.394. Introduction on the 
OH of a TBS group did not cause a significant change in activity (6, OD = 0.407), whereas a 
benzyl group in the same position (10), showed a two-fold decrease in activity (OD = 0.770, 
not significantly different from the negative control). Significance was assessed by one-way 
analysis of variance (ANOVA) and Tukey-Kramer post hoc test (significant differences 
between groups were considered at p ≤ 0.05) (see SI). 
Reduction of the ester group to introduce a polar alcohol moiety at position 4 of both TBS 
and benzyl substituted compounds gave derivatives 7 and 11 (OD = 0.647 and OD = 0.776, 
respectively). Compound 11 showed a similar activity to the corresponding ester 10, whereas 
7 showed a decreased activity compared to the ester 6. 
Having not gained potency by introducing a polar group, we replaced the ester group with an 
apolar aliphatic chain to obtain 9 and 13. Comparing the activities of 6 with 9, we observed a 
decrease of activity due to the introduction of the aliphatic chain (OD = 0.762 in 9 vs  OD = 
0.407 in 6). Interestingly, the introduction of the apolar chain on the benzyl substituted 
derivative 13 resulted in the highest antibacterial activity recorded (OD = 0.054) against S. 
mutans biofilm, not significantly different from CHX when diluted up to 0,2% w/v 
(p=1.0000).  
Successively, the effect of substituents on the nitrogen atom was investigated. Removal of the 
PMB group from compound 10 did not cause any change in activity (14: OD = 0.761). An 
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unexpected gain in antibacterial activity was observed with the introduction of the protected 
aminoacidic moiety (compound 15) (OD = 0.084).  
Indeed, the derivative 15 showed a significant decrease in the S. mutans viable biomass when 
diluted up to 0.008% w/v (p<0.0001). In the highest concentration tested (1% w/v), it showed 
an antibacterial activity not significantly different from the positive control (p=1.0000). 
Removal of the Boc protecting group (compound 16) resulted in a 5-fold lower activity (OD 
= 0.422). 
Finally, considering the significant activity showed by compound 15, we synthesized the 
corresponding derivative with a methyl in place of the benzyl group (17).. This replacement 
caused a drop in activity (OD = 0.539), suggesting that the presence of a lipophilic benzyl 
group in position 3 was productive in terms of antibacterial activity. 
Figure 2 and Table 2 report the results on antifungal activity of derivatives. Almost every 
compound possessed fungicidal activity. In particular, derivatives 10, 11, 13, 14, 15 and 17 
exhibited a concentration-dependent activity on C. albicans biofilm.  
The TBS-substituted compounds (6, 7, 9) were less effective than the corresponding benzyl-
substituted compounds, which, in turn, showed a significant activity comparable to their 
antimicrobial activity on Streptococcus mutans. Again, compounds 13 and 15 were the most 
effective antifungal agents. In fact, at the highest concentration tested, they showed an 
activity comparable to 0.2% CHX. 
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Table 2. Antimicrobial activity of pyrrolidinedione derivatives on Streptococcus mutans and 
Candida albicans. 
Compound Viable biomass (OD)1 
 S. mutans C. albicans 
5 0.394 0.160 
6 0.407 0.224 
7 0.647 0.231 
9 0.762 0.201 
10 0.771 0.198 
11 0.776 0.187 
13 0.054 0.115 
14 0.761 0.167 
15 0.084 0.144 
16 0.422 0.186 
17 0.539 0.203 
CHX2 0.051 0.147 
 
1Residual viable biomass of either a Streptococcus mutans or a Candida albicans 24h-grown monospecific 
biofilm after 1h exposure to the most active dilution of the derivative, as assessed by MTT assay (data shown as 
OD values, higher OD meaning a higher amount of adherent, viable microbial biomass after the exposure); 
2Chlorhexidine (positive control). 
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Figure 1. Residual Streptococcus mutans viable biomass after 1h exposure to different concentrations of the 
tested derivatives. The negative control (the solution used to dilute the derivatives) is shown as a green bar and 
green dashed line while the positive control (a 0.2% solution of Chlorhexidine) is highlighted in red. Data are 
presented as OD values proportional to the amount of viable bacterial cells ± 1 standard error 
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Figure 2. Residual Candida albicans viable biomass after 1h exposure to different concentrations of the tested 
derivatives. The negative control (the solution used to dilute the derivatives) is shown as a green bar and green 
dashed line while the positive control (a 0.2% solution of Chlorhexidine) is highlighted in red. Data are 
presented as OD values proportional to the amount of viable fungal cells ± 1 standard error. 
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5.2 Antifungal activity against Cladosporium cladosporioides  
We also decided to assess the activity of substituted 2,3-pyrrolidinedione-containing 
compounds against Cladosporium cladosporioides, a fungal plant pathogen that affects 
wheat. For the antifungal assay 10.0 µL of solution corresponding to 50.0, 40.0, 30.0, 20.0, 
10.0, 5.0, 1.0, 0.5, 0.1 µg were applied to precoated Si gel TLC plates. The chromatograms 
were sprayed with spore suspension of Cladosporium cladosporioides in CZAPEK broth and 
incubated for 72h in darkness in a moistened chamber at 25°C. None of compound found 
significant activity. Prochloraz was used as control.  
 
The results obtained suggest that compounds possessing a 2,3-pyrrolidinone skeleton can be 
considered promising candidates in the development of new antibacterial and antifungal 
compounds. In particular, compound 13 showed a remarkable activity both on Streptococcus 
mutans and Candida albicans. 
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5.3 Experimental  
5.3.1 Antimicrobial activity 
5.3.1.1 Microorganisms 
All the culture media were obtained from Becton-Dickinson (BD Diagnostics-Difco, Franklin 
Lakes, NJ, U.SA). A pure suspension of Streptococcus mutans (ATCC 35668) in brain-heart 
infusion (BHI) broth was obtained after 24h incubation at 37 °C in a 5% CO2 supplemented 
environment. Cells were harvested by centrifugation (2200 rpm at 19°C for 5 min), washed 
twice with sterile phosphate-buffered saline (PBS) and resuspended in the same buffer. The 
cell suspension was subsequently subjected to low intensity ultrasonic energy (Sonifier model 
B-150; Branson, Danbury, CT, USA; operating at 7W energy output for 30 s) in order to 
disperse bacterial chains. Then, the suspension was adjusted to a turbidity equivalent to that 
of a 1.0 McFarland standard. 
A pure suspension of Candida albicans (ATCC 90028) in BHI broth was obtained after a 24h 
incubation at 37 °C in a 5% CO2 supplemented environment. Cells were harvested by 
centrifugation (2200 rpm at 19 °C for 5 min), washed twice with sterile PBS and resuspended 
in the same buffer and, then, the suspension was adjusted to a value of 1.0 on McFarland 
scale. The concentration for both the tested strains was confirmed by plate-count on Mitis 
salivarius agar (MSA) and on Sabouraud dextrose agar (SDA) for S. mutans and C. albicans 
suspensions, respectively. 
5.3.1.2 Solutions of derivatives 
All reagents, including the multi-well plates used in this study were purchased from Sigma-
Aldrich (Sigma-Aldrich, St. Louis, MO, USA), unless otherwise specified. Solutions of the 
tested compounds were prepared for each derivative using 10% (v/v) DMSO and 10% (v/v) 
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EtOH in sterile PBS. The following dilutions were prepared for each derivative: 1%, 0.2%, 
0.04%, 0.008%, w/v. A solution consisting in10% (v/v) DMSO + 10% (v/v) EtOH in sterile 
PBS was used as negative control, whereas another solution of 0.2% chlorhexidine (CHX) in 
10% (v/v) DMSO + 10% (v/v) EtOH in sterile PBS was used as positive control. Finally, all 
solutions were filter-sterilized (Millipore filter, 0.2µm). The researchers who assessed the 
microbiological activity of the solutions were blinded regarding the derivatives and the 
dilutions of the tested solutions. 
5.3.1.4 Biofilm formation 
Two independent experimental runs were performed in two different months in order to 
exclude day-to-day variability, and data from the two runs were averaged. 
In each well of 96 well-plates, 200 µL of sterile TSB broth additioned with 1% D-glucose 
(Klein et al., 2014) and 20 µL of cell suspension were inoculated. The plates were then 
incubated at 37°C and 5% CO2 supplemented atmosphere for 24 h to allow the development 
of a multilayer biofilm on the polystyrene surfaces. After that, the supernatant broth solution 
was gently removed and each well was gently rinsed with sterile PBS in order to remove non-
adherent cells. Then, the rinsing solution was discarded and 25 µL of each dilution of the 
tested derivative solutions were added to each well. A total of 14 replicate wells were 
inoculated in tandem for each solution and strain. After 1h, the test solutions were discarded 
and the wells were gently rinsed with sterile PBS. The residual viable biomass on the 
polystyrene surfaces was evaluated for both tested strains by the MTT assay.  
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5.3.1.5 MTT assay 
The MTT assay was conducted as follows: a tetrazolium salt (MTT) stock solution was 
prepared by dissolving 5 mg mL-1 3-(4,5)-dimethylthiazol-2-yl-2,5-diphenyltetrazolium 
bromide in sterile PBS; a phenazinium salt (PMS) stock solution was prepared by dissolving 
0.3 mg mL-1 of N-methylphenazinium methyl sulphate in sterile PBS. The solutions were 
stored at 4°C in light-proof vials until the day of the experiment, when a fresh measurement 
solution (FMS) was prepared by mixing 1 mL of MTT stock solution, 1 mL of PMS stock 
solution and 8 mL of sterile PBS for each 96-well plate. A lysing solution (LS) was also 
prepared by dissolving 10% v/v of sodium dodecyl sulphate (SDS) and 50% v/v of 
dimethylformamide (DMF) in distilled water. 
At the end of the incubation period, the adherent, viable and metabolically active biomass 
was measured by MTT assay as follows. At first, 100 µL of FMS were added in each well 
and the plates were incubated at 37°C in light-proof conditions, for 30 min (S. mutans) or 3h 
(C. albicans). During incubation, electron transport across the microbial plasma membrane 
and, to a lesser extent, microbial redox systems converted the yellow MTT salt to insoluble 
purple formazan. The conversion was facilitated by the intermediate electron acceptor (PMS). 
The unreacted FMS was gently removed from the wells by aspiration and the formazan 
crystals were dissolved by adding 100 µL of LS to each well; plates were then incubated for 
1h at room temperature in light-proof conditions. From each well, 80 µL of the suspension 
were collected and optical density (OD) at 550 nm was measured with a spectrophotometer 
(Genesys 10-S, Thermo Spectronic, Rochester, NY, USA). OD units are proportional to the 
number of adherent, viable cells in each well. 
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5.3.2 Statistical analysis 
Statistical analyses were carried out using JMP 10.0 software (SAS Institute, Cary, NC, 
U.S.A.). Homogeneity of variance was preliminarily checked and verified using Bartlett’s 
test. One-way analysis of variance (ANOVA) and Tukey-Kramer post hoc test were used to 
assess significant differences between groups at p ≤ 0.05. 
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                                                  CHAPTER 6 
                         Approach towards synthesis of 3-O-Methylfunicone 
6.1 Introduction  
               The structures of funicone-related compounds are based on a Ȗ-pyrone ring which is 
linked through a keto function to a ȕ-resorcylic acid nucleus whose carboxylic group is 
esterified by methanol; depending on the specific metabolite, one or more hydroxyl groups 
may be methylated, while several substitutions occur at the carbon atoms of the Ȗ -pyrone 
nucleus. The family embraces a number of derivatives showing promising biomedical 
potential as fungicides, antiviral and antitumor candidates. Funicone (1) was first isolated 
from Penicillium funiculosum1 but structural analogs have been reported from many other 
terrestrial fungi. Some funicone-related products differ by just one or few substitutions on 
this fundamental molecular frame. This is the case of isofunicone (2), a structural isomer 
produced by an unidentified Penicillium strain2, in which a methoxyl group on the aryl 
moiety is interchanged with the hydroxyl group on the Ȗ -pyrone nucleus. 
6.2 Isolation and Biological activity of 3-OMF 
3-OMF(3), produced by soil strain of P. Pinophilum3 shows consistent fungitoxic properties 
that suppressed in vitro mycelial growth of a number of plant pathogenic fungi, such as R. 
solani, A. alternata, Cylindrocladium scoparium and F. solani, at a concentration of 100 
µg/mL4. The same concentration also inhibited dermatophytic species, such as Trichophyton 
rubrum and Microsporum canis, while, as already pointed out for other compounds of the 
series, it was not effective against C. albicans5. Antiproliferative properties by 3-O-
methylfunicone have later resulted against human tumor cell lines. In fact, cytostatic effects 
and the induction of programmed death were observed on HEp-2 cells (derived from larynx 
carcinoma) at a concentration of 60 µg/ml6.The anti-proliferative effects of 3-OMF were 
 174 
investigated on human breast cancer MCF-7 cells selected as mammospheres derived from 
MCF-7s. 
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6.3 Reported Syntheses of 3-OMF 
The total synthesis of the natural product 3-OMF(3), a member of the funicone class of 
compounds, and its derivative is reported7. The key reaction in synthesis was TMPZnCl. 
LiCl-mediated halogenations and carbonylative Stille cross coupling . 
Scheme 6.1 Reported Retrosynthesis of 3-OMF 
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The synthesis of Rapicone is shown in scheme 6.2.  
Rapicone was synthesised from commercially available methyl 3,5-dimethoxybenzoate 5 and 
kojic acid 7. Methyl 2-iodo-3, 5-dimethoxybenzoate 6 was synthesised from 5 by using NIS 
in ACN with 82%. Kojic acid was converted into allo maltol 8 in two steps with 50% yield. 
To convert this synthon into a tin–organyl, the hydroxy group was triflated to provide 9. 
Subsequent direct stannylation with hexamethylditin afforded the cross-coupling partner 10. 
The carbonylative Stille cross-coupling reaction with 6 using the Pd(OAc)2/X-Phos system 
yielded the final product rapicone 4. 
For the synthesis of 3-OMF, they have started with maltol (11), cheap commercially available 
compound (scheme 6.3). The methoxy group was introduced by methylation with 
iodomethane to afford 12 in 95% yield. Regioselective monobromination at allylic position 
was achieved by using NBS and AIBN to provide bromide 13.The bromide was substituted in 
aqueous dioxane to afford alcohol 14, which was subjected to DMP oxidation to yield 
aldehyde 15. The aldehyde 15 was then converted to alcohol 16 by using diethyzinc  and (-) 
MIB in 50% yield. The alcohol was protected with TBS group giving 17. The protected 
pyranone was regioselectively iodinated at α position with TMPZnCl.LiCl in 99% yield. The 
stannylation of iodide with Sn2Me6, LiCl, Pd(PPh3)4, in THF afforded stannane 19. The 
carbonylative Stille coupling followed by deprotection and dedydration afforded 3-OMF. 
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Scheme 6.2 
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Reagents and Conditions 
a) NIS, ACN, 82oC, 59% b) i) SOCl2, rt ii) Zn, HCl, H2O,75oC  50% over 2 steps c) Tf2O, Py, 
0oC to rt, 90% d) Sn2Me6,LiCl, Pd(OAc)2/X-Phos,DMF, rt, 81% e) Pd(OAc)2/X-Phos, CsF, 
CO(5bar), dioxane, 95oC, 50% 
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Scheme 6.3  
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Reagents and Conditions 
a) MeI, K2CO3, Acetone, 56oC, 95% b) NBS, AIBN, CCl4, 77oC, 85% c) CaCO3, 
H2O/dioxane, 100oC, 94% d) DMP, DCM, rt, 98% e) (-)MIB, Et2Zn,THF,-78 oC 
to rt, 50% f) TBSOTf, 2,6-lutidine, DCM,0 oC,82% g) TMPZnCl.LiCl, I2, THF, rt, 
99% h) Sn2Me6,LiCl, Pd(PPh3)4,THF,65oC,83% I) Pd(OAc)2/X-Phos, CsF, 
CO(5bar), dioxane, 95oC,67% j) PTSA, toluene, 110oC, 50% 
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6.4 Retrosynthesis of 3-OMF 
Our initial retrosynthetic analysis is outlined in scheme 6.4. In the beginning we envisioned 
that 3-OMF could be constructed by a convergent synthetic strategy. The subunit 21 could be 
constructed from 3,5dihydroxybenzoic acid 31 and subunit 22 could be constructed from 
ethyl 4-chloroacetoacetate 23. 
 
Scheme 6.4 
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6.5 Approach towards 3-OMF based on Suzuki coupling 
In order to construct the Ȗ-pyrone, we started from commercially available ethyl 4-
chloroacetoacetate. Ethyl 4-(allyloxy)-3-oxobutanoate 24 was obtained in 78% yield8 from 23 
by using allyl alcohol and NaH. The enaminone 25 was synthesised in good yield by using 
DMF-DMA at RT9. Further cyclisation of enaminone 25 to Ȗ-pyrone was failed. 
Scheme 6.5 
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Reagents and conditions: 
a) Allyl alcohol, NaH, THF, 0°C to RT, 16h, 78%  b) DMF.DMA, RT,16h, 90%   
Ethyl 4-(benzyloxy)-3-oxobutanoate 26 was synthesised from 23 by using BnOH and NaH in 
70% yield10. Subsequently, 26 was reacted with DMF-DMA to obtain enaminone 27 in 91% 
yield. Compound 27 was cyclised by using cinnamoyl chloride and LiHMDS at -78oC to give 
Ȗ-pyrone moiety 28. The ester of 28 was hydrolysed in basic condition in EtOH:water to 
afford acid 29. Further acid chloride 30 was synthesised from acid 29 by using oxalyl 
chloride and cat.DMF at 0oC in 63%. 
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Scheme 6.6 
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Reagents and conditions: 
a) BnOH, NaH, THF, 0°C to RT, 16h, 70%  b) DMF.DMA, RT,16h, 91% c) Cinnamoyl 
chloride, LiHMDS, -78°C  to RT , 1h, 60% d) NaOH, EtOH:Water, 0°C to RT,72% d) Oxalyl 
chloride, DMF, DCM, 0°C to RT,63% 
 
After developing a successful procedure for acid chloride of Ȗ-pyrone moiety, we have 
synthesised the aromatic boronate ester. Methyl 3,5-dimethoxybenzoate 32 was prepared 
from 3,5-dihydroxybenzoic acid 31 by using dimethyl sulphate and K2CO3 in 98% 
yield11.The regioselective bromination of 31 was carried out by using NBS in ACN in 75%12. 
Aryl boronate ester 34 was synthesised by Miyaura boraylation reaction in 67%13. The 
hydrolysis of boronate ester to boronic acid under different conditions failed. 
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Reagents and conditions: 
a) Dimethyl sulphate, K2CO3, acetone, reflux, 4h, 98% b) NBS, ACN, 0°C to RT, 24h, 75% 
c) Bis(pinacolato)diborane, K3PO4, (dppf)2PdCl2.dcm, dioxane, reflux, 12h, 67%. 
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A few attempts to couple boronate 34 and acid chloride 30 failed as well. Now work is in 
progress to find the conditions for Suzuki coupling of the two key fragments obtained.  
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                                                 6.6 Experimental 
 
                                    Ethyl 4-(allyloxy)-3-oxobutanoate                                                    
                                                  
O
O O
O
24
 
 
 A solution of allyl alcohol (3.3 mL, 47 mmol) in THF (17 mL) was added to a stirred 
suspension of sodium hydride (60% dispersion in oil; 3.8 g, 94 mmol) in THF (33 mL) at 
0°C, and the resulting mixture was stirred at 0°C for 1 h, then at reflux for 1 h, then cooled to 
0°C. A solution of ethyl 4-chloroacetoacetate (4.94 mL, 36.7 mmol) in THF (17 mL) was 
added dropwise over 2 min, and the resulting mixture was allowed to warm to room 
temperature with stirring over 16 h. The mixture was acidified to pH 2 by dropwise addition 
of hydrochloric acid (1 M). Water (50 mL) and ethyl acetate (50 mL) were added. The 
aqueous phase was further extracted with ethyl acetate (3 × 50 mL) and the combined organic 
phases were dried (MgSO4), filtered and concentrated in vacuo. The crude product was 
purified by flash column chromatography (10% EtOAc/Hexane) to afford 24 (5.32 g, 78%) 
Physical appearance Pale yellow liquid 
Rf  0.5(EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 5.88 (1H, m); 5.28 (2H, m); 4.30-4.00 (6H, m); 3.65 (2H, m); 1.27 (3H, 
t, J = 7.2 Hz). 
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         (Z)-Ethyl 4-(allyloxy)-2-((dimethylamino)methylene)-3-oxobutanoate  
                                                          
                                                               
O
O O
O
N 25
 
A mixture of N, N-Dimethylformamide dimethyl acetal (DMF-DMA) (0.153 g, 1.288 mmol) 
and ethyl 4-(allyloxy)-3-oxobutanoate 24 (0.2 g, 1.073 mmol) was allowed to stir for 24h at 
rt. After the completion of reaction, crude was purified by column chromatography (90% 
EtOAc/Hexane) afforded 25 (0.207 g, 90%) 
Physical appearance Yellow viscous liquid 
Rf 0.5(EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.71 (1H, s); 5.92 (1H, m); 5.40-5.12 (2H, m); 4.42 (2H, s); 4.19 (2H, q, 
J = 7.3 Hz); 4.04 (2H, d, J = 5.5 Hz); 3.25 (3H, brs); 2.90 (3H, brs); 1.30 (3H, t, J = 7.3 Hz). 
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                                           Ethyl 4-(benzyloxy)-3-oxobutanoate 
                                                        
                                                                 
O
O O
OBn
26
 
 
Benzyl alcohol (0.722 g, 6.683 mmol) was added dropwise to a stirred suspension of 60% 
sodium hydride (0.65 g, 13.36 mmol) in THF (20 mL); occasional cooling was required with 
an ice bath to maintain ambient temperature. After hydrogen evolution ceased, the thick 
slurry was allowed to stir for 2 h. Ethyl 4-chloroacetoacetate (1.00 g, 6.075 mmol) was then 
added dropwise within 3 h, and the reaction mixture was stirred for 16 h. The reaction 
mixture was carefully added into 5% HCl solution (200 mL) at 5 °C and extracted with 
EtOAc (100 mL × 3). The organic layers were washed with saturated NaHCO3 (60 mL x 2) 
and then saturated NaCl (60 mL), dried over anhydrous Na2SO4, filtered, and concentrated in 
vacuo. The crude product was purified by silica gel chromatography (10% EtOAc/Hexane) 
 to give 26 (1.02 g, 70%) 
Physical appearance Yellow liquid 
Rf 0.4 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3): 1.25 (3H, t, J=7.2 Hz), 3.54 (2H, s), 4.14 (2H, s), 4.17 (2H, q, J=7.2 
Hz), 4.59 (2H, s), 7.28-7.40 (5H, m). 
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             (Z)-Ethyl 4-(benzyloxy)-2-((dimethylamino)methylene)-3-oxobutanoate 
                                                                    
O
O O
OBn
N 27
 
A mixture of N, N-Dimethylformamide dimethyl acetal (DMF-DMA) (0.32 g,  2.53 mmol) 
and ethyl 4-(benzyloxy)-3-oxobutanoate 26 (0.50 g, 2.11 mmol) was allowed to stir for 24h at 
rt. After the completion of reaction, the crude was purified by column chromatography (90% 
EtOAc/Hexane) to give 27 (0.53 g, 91%) 
Physical appearance Yellow liquid 
Rf 0.5 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.74 (1H, s); 7.42-7.24 (5H, m); 4.60 (2H, s); 4.47 (2H, s); 4.16 (2H, q, 
J = 7.2 Hz); 3.25 (3H, brs); 2.92 (3H, brs); 1.26 (3H, t, J = 7.2 Hz). 
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                     Ethyl 5-(benzyloxy)-4-oxo-6-styryl-4H-pyran-3-carboxylate 
                                                    
O
O
OBn
Ph
O
O
28
 
A 1N LiHMDS in THF (0.858 mL, 0.85mmol) solution was cooled to -78oC and a solution of 
compound 27 (0.10 g, 0.343 mmol) and cinnamoyl chloride (0.068 g, 0.411mmol) in THF 
was added dropwise over 10 min while same temperature was retained. The reaction mixture 
was stirred for 45 min at -78oC and then quenched with 2N HCl at 0oC, stirred for 15min, 
extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The crude product was purified by flash column chromatography (18% 
EtOAc/Hexane) to afford 28 (0.077 g, 60 %) 
Physical appearance White solid  
Rf 0.5 (EtOAc/Hexane 3:7) 
1H NMR (CDCl3) : 8.44 (1H, s); 7.60-6.90 (6H, m); 6.45 (1H, d, J = 16.2 Hz); 5.27 (2H, s); 
4.38 (2H, q, J = 7.2 Hz); 1.38 (3H, t, J = 7.2 Hz). 
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                   5-(Benzyloxy)-4-oxo-6-styryl-4H-pyran-3-carboxylic acid 
                                                            
O
O
OBn
Ph
HO
O
29
 
To the stirred solution of compound 28 (0.75 g, 1.99 mmol) in EtOH:Water(3:1) was added 
NaOH (0.12 g, 2.98 mmol) at 0oC, then the solution was allowed stir for 4h at rt. After the 
completion of reaction, the mixture was concentrated in vacuo. The crude was acidified with 
2N HCl at 0oC, extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated to give acid 29 (0.5 g, 72%) 
Physical appearance Yellow solid 
Rf 0.2 (MeOH/DCM 1:9) 
1H NMR (CDCl3) : 9.78 (1H, s); 7.81-6.80 (7H, m); 5.02 (2H, s). 
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                    5-(Benzyloxy)-4-oxo-6-styryl-4H-pyran-3-carbonyl chloride 
                                                
O
O
OBn
Ph
Cl
O
30
 
To the stirred solution of 29 (0.06 g, 0.17mmol) in dry DCM (3 mL) was added oxalyl 
chloride (0.043 g, 0.344 mmol) and cat. DMF (1drop) at 0oC, then the reaction mixture was 
allowed to stir for 5h at rt. After the completion of reaction, the mixture was concentrated in 
vacuo. The crude product was purified by silica gel chromatography (10% EtOAc/Hexane) to 
give 26 (0.04 g, 63%) 
Physical appearance Yellow viscous liquid 
Rf 0.5 (EtOAc/Hexane 1:9) 
1H NMR (CDCl3) : 7.54-7.32 (7H, m); 6.80 (1H, d, J = 15.8 Hz); 5.00 (2H, s). 
 
 
 
 
 
 
                                          
 
 189 
                                     Methyl 3,5-dimethoxybenzoate 
                                                                   
O O
OO
32
 
To 3,5-dihydroxybenzoic acid 31 (15.4 g, 0.1 mol) dissolved in acetone (150 mL) was added 
potassium carbonate (42.8 g, 0.3 mol, 3.1 equiv.) followed by dimethyl sulphate (19 mL, 2 
equiv.). The mixture was then heated to reflux for 4 h with vigorous stirring. Upon cooling to 
room temperature, water was added so as to completely dissolve all the potassium carbonate 
and the mixture extracted with diethyl ether (3 x 30 mL). The combined organic extracts were 
dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford 32 (16.58 g, 
98%) 
 
Physical appearance White solid 
Rf 0.5 (EtOAc/Hexane 1:9) 
1H NMR (CDCl3) :   7.17 (2H, d, J = 2.4 Hz,), 6.63 (1H, t, J = 2.4 Hz,), 3.88 (3H, s), 3.81 
(6H, s) 
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                                  Methyl 2-bromo-3,5-dimethoxybenzoate 
                                                            
O O
OO
Br
33
 
 Methyl 3,5-dimethoxybenzoate 32 ( 0.115 g, 0.586 mmol) in acetonitrile ( 3 mL) was treated 
with N-bromosuccinimide (0.125 g, 0.703 mmol) at 0°C and the solution was stirred at room 
temperature for 24h. After removal of the solvent, the residue was purified by column 
chromatography (PE/Et2O, 2:1), yielding the desired compound 33 (0.12 g, 75%) 
Physical appearance White solid 
Rf 0.3(EtOAc/Hexane 1:9) 
1H NMR (CDCl3) : 6.82 (1H, d, J = 2.7 Hz); 6.60 (1H, d, J = 2.7 Hz); 3.95 (3H, s); 3.91 
(3H, s); 3.84 (3H, s). 
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       Methyl 3,5-dimethoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
                                                          
O O
OO
B O
O
34
 
The aromatic bromide (0.1 g, 0.363 mmol) was dissolved in dioxane (5 mL) and cooled to -
78°C and vacuum degassed and back filled with nitrogen. To this degassed reaction mixture 
were added bis(pinacolato)diborane (0.12 g, 0.472 mmol), K3PO4 (0.23 g, 1.090 mmol) and 
(dppf)2PdCl2. DCM (0.015 g, 0.0181 mmol). The reaction mixture was refluxed overnight 
under nitrogen. After the completion of reaction, the mixture was filtered through a celite bed 
and washed with EtOAc. The organic layer was washed water and brine solution. The 
combined organic extracts were dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude was purified by column chromatography (20% EtOAc/Hexane) 
to give 34 (0.09 g, 67%) 
Physical appearance White solid 
Rf 0.6 (EtOAc/Hexane 2:8) 
1H NMR (CDCl3) : 7.10 (1H, d, J = 1.8 Hz); 6.58 (1H, d, J = 1.8 Hz); 3.91 (3H, s); 3.84 
(3H, s); 3.79 (3H, s); 1.43 (12H, s). 
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                                                         CHAPTER 7 
 
Conclusions 
1. The first total synthesis of the natural compound Leopolic acid A was designed and carried 
out. The synthesis of Leopolic Acid A has been achieved starting from commercially 
available amino acids L-Valine and L-Phenyl alanine in 11 steps. 
2. During the synthesis of the natural compound Leopolic acid A an oxazolidone analogue of 
Leopolic acid A was also synthesized. This core structure is new and a survey of the literature 
showed that compounds with this scaffold have never been isolated or synthesized before. 
Studies to evaluate its biological activity are underway. 
3. A series of compounds containing the 2, 3-pyrrolidinedione skeleton were prepared, 
considering a combination of substituents at different positions to have a large variety of 
structurally diverse molecules. The antifungal and antimicrobial activity of these compounds 
were evaluated and preliminary structure-activity relationship (SAR) have emerged. 
4. An approach towards total synthesis of the positional isomer of natural compound Leopolic 
acid A was developed. 
5. Efforts were directed towards the total synthesis of natural compound 3-O-
Methylfunicone.  
 
 
 
 
